US20090192486A1 - Automatic injector with anti-coring needle - Google Patents
Automatic injector with anti-coring needle Download PDFInfo
- Publication number
- US20090192486A1 US20090192486A1 US09/985,466 US98546601A US2009192486A1 US 20090192486 A1 US20090192486 A1 US 20090192486A1 US 98546601 A US98546601 A US 98546601A US 2009192486 A1 US2009192486 A1 US 2009192486A1
- Authority
- US
- United States
- Prior art keywords
- needle
- cartridge
- housing
- medicament
- forward end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/28—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle
- A61M5/285—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened
- A61M5/286—Syringe ampoules or carpules, i.e. ampoules or carpules provided with a needle with sealing means to be broken or opened upon internal pressure increase, e.g. pierced or burst
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3286—Needle tip design, e.g. for improved penetration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2006—Having specific accessories
- A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/206—With automatic needle insertion
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2073—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically preventing premature release, e.g. by making use of a safety lock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
- A61M2005/2086—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically having piston damping means, e.g. axially or rotationally acting retarders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31501—Means for blocking or restricting the movement of the rod or piston
- A61M2005/3151—Means for blocking or restricting the movement of the rod or piston by friction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/19—Constructional features of carpules, syringes or blisters
- A61M2205/192—Avoiding coring, e.g. preventing formation of particles during puncture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/19—Constructional features of carpules, syringes or blisters
- A61M2205/192—Avoiding coring, e.g. preventing formation of particles during puncture
- A61M2205/195—Avoiding coring, e.g. preventing formation of particles during puncture by the needle tip shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/3129—Syringe barrels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/329—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles characterised by features of the needle shaft
- A61M5/3291—Shafts with additional lateral openings
Definitions
- the present invention relates to automatic injectors, and more particularly, to automatic injectors that reduce the likelihood of coring a sealing member.
- an automatic injector is a device for enabling an individual to self-administer, or administer to another, a dosage of a liquid medicament.
- An advantage of automatic injectors is that they contain a measured dosage of a liquid medicament in a sealed sterile condition capable of storage in such condition for an extensive period of non-use, during which period immediate injection of the stored dosage may be accomplished at any time under severe emergency conditions.
- Another advantage of automatic injectors is the administration of the self-contained dosage of liquid medicament is accomplished without the necessity of the user initially seeing the hypodermic needle through which the liquid medicament is injected or of manually penetrating such visible needle into the user's or another person's tissue.
- automatic injectors are particularly suited for use under emergency conditions. For example many tens of millions of such automatic injectors have been manufactured and sold containing nerve gas antidotes for use under emergency chemical warfare conditions. Typical units which have been utilized for this purpose are disclosed in U.S. Pat. Nos. 2,832,339, 3,882,863, and 4,031,893. In addition units of this type have been manufactured and used in administering anti-arrhythmic medicaments under emergency conditions relating to heart attack medical situations. The use of an auto injector has also been proposed to provide other medicaments useful in treating heart attack symptoms such as clot selective thrombolic agents (for example, tPA) and related medicaments. See for example, U.S. Pat. Nos.
- tPA clot selective thrombolic agents
- automatic injectors have been widely marketed containing a dosage of epinephrine as an antidote for counteracting severe allergic reactions, as for example, to bee stings, and the like.
- the auto-injector is specifically structured so that in its normal operation the needle extends into the tissue of the individual and a specified amount of liquid medicament stored in a cartridge within the injector is injected into the tissue of the individual.
- the hypodermic needle of an autoinjector has a forward end adapted to penetrate the clothing and flesh of an individual and a rearward end adapted to communicate with a liquid medicament source so that the medicament is permitted to flow from the source, through the central longitudinal bore or lumen in the needle, and into the flesh of the individual.
- the needle is contained inside the cartridge containing the liquid medicament.
- a tubular container or cartridge generally made of glass, plastic or metal, having a rubber seal closing off at the forward end and a rubber plunger at the rearward end.
- U.S. Pat. No. 5,354,286 see U.S. Pat. No. 5,354,286.
- a stressed spring assembly is released moving a push rod against the plunger.
- the plunger pushes against the hub-end of the needle causing the needle to puncture the forward end seal of the cartridge and penetrates into the flesh of an individual.
- the liquid medicament is pushed at the same time through the needle, thus releasing the medicament into the individual's flesh.
- the needle is connected to the forward end of the cartridge. See U.S. Pat. No. 5,102,393.
- the needle is forced through a resilient seal at the forward end of the outer housing or through an elongated rubber sheath surrounding the needle.
- the needle is kept sterile by a seal disposed toward a forward end of the housing while the injector is stored. After the needle punctures the seal or sheath, it then is forced into the flesh of the individual.
- an automatic injector that comprises: a housing; a seal structure disposed toward a forward end of the housing; a cartridge contained within the housing; a charge of medicament contained in the cartridge; a plunger normally disposed in a generally rearward end of the cartridge and movable through the cartridge toward a generally forward end thereof in response to an actuating procedure.
- the movable plunger rearwardly confines said medicament within said cartridge.
- a needle is normally disposed within the housing, the needle being projectable from a forward end of said housing through said seal structure. The needle is communicable with the medicament so that movement of the plunger through the cartridge forces the medicament through the needle and into the flesh of an individual, in response to the predetermined actuating procedure.
- a releasable energy source is releasable in response to the predetermined actuating procedure to project the needle from the forward end of the housing and slidingly drive the plunger through the cartridge in sealed relation to expel the medicament through the needle and into the flesh of an individual.
- the cartridge has an increased friction region so as to slow the motion of the plunger as the forward end of the needle travels through the seal.
- the needle carries a damping structure for reducing the rate of acceleration of the needle by the resistance created when said damping structure moves within said medicament.
- the present invention is directed to several automatic injection devices comprising novel needle structures that reduce coring of an elastic, plastic or rubber based structure at the forward end of the injector.
- FIG. 1 is a longitudinal sectional view of an automatic injector according to an embodiment of the present invention
- FIG. 2 is a longitudinal sectional view of a cartridge showing the friction region according to an embodiment of the present invention
- FIG. 3 is a longitudinal sectional view of the cartridge showing the friction region according to an alternative embodiment of the present invention.
- FIG. 4 is a graph showing the force versus distance of travel of plunger in a configuration without an increased friction region, as will be described hereinafter;
- FIG. 5 is a graph showing the force versus distance of travel of plunger in a configuration when using embodiment illustrated in FIG. 3 ;
- FIG. 6 is a graph showing the force versus distance of travel of plunger in a configuration when using embodiment illustrated in FIG. 2 ;
- FIG. 7 is a graph showing the percentage of coring versus the inside diameter measured at an increased friction region, as will be described hereinafter;
- FIG. 8 is a graph showing the core length versus the inside diameter measured at an increased friction region, as will be described hereinafter;
- FIG. 9 is an enlarged view of a straight tip showing the point and the heel of the needle.
- FIG. 10 is a longitudinal sectional view of the hypodermic needle as installed in a cartridge according to another embodiment of the present invention; the hypodermic needle is shown having a curved tip;
- FIG. 11A is an enlargement of the tip of the needle according to embodiment illustrated in FIG. 10 having curved “C” tip;
- FIG. 11B is an enlargement frontal view of the pointed tip of the needle
- FIG. 12 is a longitudinal expanded sectional view of the forward end of the needle showing the interaction of the seal material with a curved tip needle having a regular/thinner wall thickness;
- FIG. 13 is a longitudinal expanded sectional view of the forward end of the needle show the interaction of the seal material with a needle having a heavy/thicker wall thickness
- FIG. 14 is a longitudinal expanded sectional view of the forward end of the needle showing the curvature tolerance limits
- FIG. 15 is a longitudinal expanded sectional view of the forward end of the needle showing the front-ground geometry
- FIG. 16 is a sectional transversal view of the forward end of the needle showing the front-ground geometry
- FIG. 17 is a longitudinal expanded sectional view of the forward end of the needle showing the back-ground geometry
- FIG. 18 is a sectional transversal view of the forward end of the needle showing the back-ground geometry
- FIG. 19 shows the consecutive transversal sectional views of the forward end of the needle illustrating the back-ground geometry
- FIG. 20 shows consecutive transversal sectional views of the forward end of the needle illustrating the front-ground geometry
- FIG. 21 is a longitudinal view of the forward end of the needle according to an alternative embodiment of the present invention where Parylene coating is applied to the needle;
- FIG. 22 is a longitudinal expanded view of the heel of needle according to embodiment illustrated in FIG. 21 .
- the heel is shown uniformly coated with a conformal coating;
- FIG. 23 is a graph showing the percentage of coring and the coring mean length versus the coating thickness as applied in embodiment illustrated in FIG. 22 ;
- FIG. 24 is a longitudinal sectional view of an automatic injector according to another embodiment of the present invention.
- the automatic injector 100 includes a tubular housing 102 , a medicament cartridge assembly 104 , within the forward end portion of the housing assembly 102 , and a releasable energy source 106 which is releasable in response to a predetermined actuating procedure as will be described in detail in the following paragraphs.
- the releasable energy source can be any type of assembly which effectuates an injection operation, such as a compressed gas assembly as disclosed in U.S. Pat. No. 4,518,384, it is preferred that the releasable energy source be a stressed spring assembly, as generally indicated at 106 .
- the stressed spring assembly is disposed within the rearward end portion of the housing assembly 102 in operative relation with the medicament cartridge assembly 104 .
- a releasable end safety cap 108 positioned at the rear of the housing assembly 102 is in operative relation with the stressed spring assembly 106 .
- the housing assembly 102 , medicament cartridge assembly 104 , and stress spring assembly 106 are generally constructed in accordance with the teaching of U.S. Pat. No. 2,832,339, hereby incorporated by reference.
- the housing assembly 102 includes a cylindrical outer housing member 110 having a centrally apertured cylindrical rear wall portion 112 of reduced diameter on which the safety end cap 108 is mounted.
- the housing assembly 102 also includes an inner cylindrical housing member 114 within the housing member 110 within which is mounted the medicament cartridge assembly 104 and the stressed spring assembly 106 .
- the forward portion of the inner housing member 114 is formed with a counterbore for receiving therein a cylindrical dosage container or cartridge 116 of the medicament cartridge assembly 104 .
- the cartridge of the present invention is preferably made of metallic materials such as, but not limited to, stainless steel and aluminum. Other materials, such as plastic materials (eg., polypropylene) or glass are also within the scope of the present invention.
- the forward end of the container or cartridge 116 is closed by a stopper or seal 118 , preferably, of suitable rubber or compliant plastic material.
- the cartridge assembly 104 is retained in closing relation with the forward end of the inner housing member 114 by a housing end cap member 120 of molded plastic material.
- the cap 120 is preferably retained on the inner housing member 114 by inter-engagement of a pair of ridges 122 formed on the exterior periphery of the tubular member 114 with an annular groove 124 formed on the interior periphery of the cap member 120 .
- the rearward end of the cartridge 116 is closed by a rubber or plastic plunger 126 which is slidably, sealingly engaged with the inner surface of cartridge 116 so as to enclose within the cartridge a dosage 128 of a liquid medicament.
- a hypodermic needle 130 is disposed within the cartridge 116 .
- the cartridge assembly 104 includes cartridge 116 , seal 118 , needle 130 and disc 132 .
- needle 130 is normally stored in contact with the medicament 128 .
- needle 130 can be disposed in a separate chamber (either evacuated or filled with a preferably inert gas) forwardly of the medicament 128 (for example, see our U.S. Pat. Nos. 5,085,642 and 5,102,393), so long as the needle is somehow communicable with the medicament in a manner which permits the medicament to travel through the needle and into the flesh of an individual.
- the needle can also be disposed in contact with one of two medicaments, which are normally stored separately within the injector and then either mixed within the injector prior to an injection (e.g. see U.S. Pat. No. 5,041,088) or injected separately one after the other (see U.S. Pat. No. 5,092,843).
- the hypodermic needle 130 is preferably made from stainless steel.
- the needle 130 has its pointed end disposed within a recess formed in the seal 118 .
- a disc 132 of plastic is disposed within the forward end of the cartridge 116 in surrounding, securing and guiding relation with the hypodermic needle 130 and in abutting engagement with the seal 118 .
- the disc 132 serves to releasably hold the needle in its storage position to provide peripheral centering therefore during the dosage injecting stroke of the plunger 126 .
- the rearward end of the hypodermic needle 130 is enlarged for engagement by the plunger and has a slot 134 formed in its side wall adjacent the enlarged end for communicating the dosage 128 with the hollow interior of the hypodermic needle 130 when the plunger 126 is in engagement therewith.
- the inner housing member 114 is mounted within the outer housing member 110 for limited reciprocating movement as determined by a pair of ridges 136 formed on the exterior periphery of the tubular inner housing member 114 at a position spaced rearwardly from the pair of ridges 122 .
- the pair of ridges 136 is adapted to engage with an elongated annular groove 138 formed on the interior periphery of the outer housing member 110 .
- the stressed spring assembly 106 includes a normally compressed but releasable coil spring 142 and an elongated collet member 140 .
- the collet member is disposed within the rearward portion of the housing member 114 and has its forward end disposed adjacent to the plunger 126 .
- the forward end of the collet member 140 has a flange 141 configured to engage the forward end of the stressed coil spring 142 , which surrounds the central portion of the elongated collet member 140 .
- the collet 140 has its rearward end engaged with a locking ring 152 sitting on an annular end flange 144 formed integrally on the rearward end of the inner housing member 114 .
- the rearward end of the elongated collet member 140 are split to provide a plurality (e.g., four) flexible spring fingers 146 , the rearward extremities of which are formed with rearwardly and outwardly facing cam releasing surfaces 148 . Extending inwardly from the rearward end of each cam surface 148 is locking shoulder 150 adapted to engage a locking ring 152 seated on the rear surface of flange 144 .
- the forward portion of the apertured cylindrical wall portion 112 is formed with a complementary cam surface 154 , which is disposed in engagement with the cam surfaces 148 so as to effect a laterally inward movement of the spring fingers 146 toward one another to disengage locking shoulders 150 from locking ring 152 in response to a relative forward actuating movement of the outer housing member 110 with respect to the inner housing member 114 .
- This inward action of the spring fingers 146 is permitted only after the safety cap 108 is removed, as will be described.
- releasable end cap 108 is removed from the injector 100 .
- This removal is accomplished simply by gripping the exterior periphery of the end cap 108 and moving it rearwardly while gripping and holding the outer housing member 110 .
- the cap member 108 carries with it a safety pin portion 160 .
- the safety pin portion 160 removed from its safety position, which normally prevents the laterally inward movement of the spring fingers 146 , the user can now complete the operation by moving the forward cap member 120 into contact with the tissue of a person to be injected.
- cam surfaces 154 thereof are moved forwardly.
- the hypodermic needle 202 comprises an elongated tube, generally cylindrical terminated at the rearward end by hub 206 .
- the forward end of the needle has a pointed shape 208 , shown in more detail in enlarged FIG. 2B .
- the needle 202 is maintained along a longitudinal axis X with holder 210 .
- Needle 202 is shown housed inside cartridge 212 , containing a liquid medicament. However as stated previously needle 202 need not be inside cartridge 212 but can be arranged to be outside the medicament cartridge.
- the forward end of cartridge 212 is terminated by seal 214 to keep the liquid medicament from leaking, shown in more detail on FIG. 2B .
- the pointed end 208 of needle 202 is oriented toward seal 214 . Therefore, initially the needle 202 is disposed between plunger 204 and seal 214 .
- the plunger is shown in this figure as a one piece material, however it is understood that the plunger can be made of a plurality of pieces with various ductile constants such as a harder piece and a softer piece of rubber.
- Seal 214 is made of a flexible material, such as but not limited to, rubber. It is known that polymers behave in a ductile manner when strained at low speed and behave in a brittle manner when strained at high speed.
- the needle 202 is arranged to penetrate in a “gentle” manner into the rubber seal 214 by reducing the thrust of the needle.
- Cartridge 104 has a friction region 215 for slowing the motion of plunger 204 thus reducing the rate of acceleration of needle 202 when perforating seal 214 .
- the acceleration rate is reduced so that the speed of the needle is less than 680 inches/s when the needle pierces the seal.
- the reduction in acceleration rate is intended specifically to reduce the speed to a level at which coring will not occur.
- the speed at which the seal is pierced is also greater than 150 inches/s so that the injection operation is not delayed more than what is desirable.
- the friction region in this embodiment is a narrowed diameter portion or localized narrowed diameter portion 222 in the wall 224 of cartridge 212 .
- the narrowed diameter portion 222 also referred to as speed bump is arranged between seal 214 and plunger 204 .
- the narrowed diameter portion 222 is arranged and configured to reduce acceleration of plunger 204 , thus reducing the speed at which the needle 202 would otherwise travel when the needle tip 208 travels through seal 214 .
- the narrowed diameter portion 222 is created on the wall of the cartridge 212 with a pressure forming method, for example with a clamshell die.
- the die or a rolling process can be used to imprint a selected shape to the stainless wall of cartridge 212 .
- cylindrical rounded narrowed diameter portion around the cylindrical wall of the cartridge can be imprinted.
- the localized narrowed diameter portion 222 in the wall 224 of cartridge 212 acts as a “speed bump” by slowing down the motion of plunger 204 .
- the narrowed diameter portion 222 increases the normal force between the plunger periphery and the wall 224 of cartridge 212 , thus creating a frictional force counter to the plunger's movement.
- the narrowed diameter portion 222 increases the diametrical interference thereby increasing the friction and retarding plunger 204 movement. This slowed movement causes the needle 202 to strain the seal 214 in a more ductile mode, thus leading to a substantial reduction in coring.
- the speed bump is arranged to be only effective along a partial length of the cartridge 212 . This allows the plunger to receive the full spring force at the beginning of operation helping to overcome static friction between the plunger 204 and the cartridge 212 . The speed bump then takes effect immediately prior to the front end of the needle contacts the seal 214 . After the needle tip 208 completes its penetration of the seal 214 , the speed bump disengages making the full spring force available to ensure completeness of the injection process.
- the plunger 204 meets increased resistance when the plunger 204 reaches the narrowed diameter portion 222 .
- Plunger 204 has a plurality of ribs 230 as shown in FIG. 2C . Each time a rib 230 of the plunger 204 encounters an edge of narrowed diameter portion 222 the friction force is increased thus leading to a net decrease in injection acceleration rate.
- the friction region 300 comprises a corrugated configuration comprising a plurality of projections 302 , shown enlarged in FIG. 3B , in order to multiply the interference with the plunger 304 .
- friction region 300 can be any structure of the cartridge that slows plunger 304 . While in the embodiments shown it is the wall of the cartridge itself that performs this function, it should be appreciated that the cartridge may employ a separate structure inserted therein.
- the plunger 304 meets increased resistance when the plunger's leading rib crosses the friction region leading edge.
- the rippled shape of friction region 300 illustrated in FIG. 3 exchanges some of the aforementioned diameter decrease in the previous embodiment in exchange for a multitude of leading edges.
- FIG. 4 shows the force-distance data profile of a standard cartridge-plunger.
- the curve 400 exhibits a high static friction spike 402 followed by a constant kinetic friction stage 404 . Numerous tests are run to collect statistical data. The mean kinetic friction from the statistical data is determined to be 0.54 lb. The nearly vertical spike 406 at the terminus represents bottoming of the plunger against the seal.
- FIG. 5 shows the force-distance data profile of a cartridge having corrugated portion and a plunger, as illustrated in FIG. 3 .
- the portion of travel in which the ripples are in effect is clearly visible on curve 500 .
- the “spikiness” of data at the friction phase 502 is caused by the individual matings and separations of the individual ripples with plunger ribs.
- statistical data is acquired to allow calculation of the mean kinetic friction during the speed bump phase.
- the mean kinetic friction is determined to be 1.47 lb.
- the mean kinetic friction of the post speed bump phase, shown on FIG. 5 as phase 504 is 0.52 lb.
- FIG. 6 shows the force-distance data profile 600 of a smooth speed bump and a plunger having three ribs, as illustrated in FIG. 2 .
- the three large consecutive spikes 602 are caused by the three ribs of the plunger entering the speed bump.
- the smaller spikes 604 occur as the plunger's ribs exit the speed bump.
- statistical data is acquired to allow calculation of the mean kinetic friction during the speed bump phase.
- the mean kinetic friction during the speed bump phase is determined to be 1.71 lb.
- the mean kinetic friction of the post-speed bump phase, shown on FIG. 6 as phase 606 is similar to the data described previously.
- FIG. 7 shows the coring frequency versus the inside diameter of the cartridge at the speed bump.
- the highest point on the curve corresponds to the inside diameter 0.298′′ of the cartridge without a speed bump.
- the lowest point on the curve corresponds to the smooth (without ridges) speed bump in its intended diameter of 0.278′′.
- Statistical data showed a population of less than 1% revealed coring.
- a softer spring for pushing the plunger may be used if desired to allow a smoother transition from the diameter of cartridge without the bump to the diameter of the cartridge at the bump.
- the diameter of the particles generated by coring are also measured and reported in FIG. 8 .
- the dimension of the core (particle) decreases when the inside diameter of the cartridge at the speed bump decreases. Therefore, the speed bump has also an advantage in decreasing the size of the coring particles.
- Needle tip 900 has generally a point 902 and a heel 904 .
- the needle tip can have a curved shape instead of a straight shape as in FIG. 9 .
- FIG. 10 shows a longitudinal sectional view of the automatic injector with hypodermic needle according to another embodiment of the present invention.
- the hypodermic needle 1000 is shown having a curved tip 1002 .
- the curved leading edge 1002 of needle 1000 having a C-tip configuration pushes the material of the seal 1004 far enough away from the heel 1100 to prevent intimate contact.
- the curved arrow 1102 indicates the direction of flow of seal material relative to the movement of the needle 1000 .
- the arrow indicates in particular that the seal material flows around the curved tip 1002 .
- the curved tip 1002 acts as a shield for the orifice or lumen 1104 of needle 1000 , by blocking the seal material 1004 from penetrating through the orifice 1104 .
- the extent to which the needle tip is curved over the orifice influences seal coring frequency.
- FIG. 11B shows an enlargement frontal view of the pointed tip 1110 of the needle.
- the curved forward tip 1114 is shown completely shielding lumen 1112 thus protecting lumen 1112 of being in direct contact with the seal material as previously discussed.
- the bent tip 1114 shields the entire cross-section of the longitudinal passage in the needle.
- FIG. 12 shows the interaction of seal material 1200 with needle 1202 having a regular wall thickness, preferably between 0.0055 inch and 0.0065 inch.
- FIG. 13 show the interaction of seal material 1300 with needle 1302 having a thicker wall (heavy wall) preferably between 0.0083 inch and 0.0090 inch.
- FIG. 13 illustrates that in the case of needle with heavy wall thickness 1302 , the heel 1304 is further away from the seal material 1300 , thus further reducing coring potential compared to needle with regular wall thickness 1202 .
- Testing shows that in the eventuality cores are produced, cores are generally smaller when using heavy-wall needles versus regular wall needles of similar geometry.
- FIG. 14 shows the geometry of the C-tip needle 1400 with manufacturing limits for the hard C-tip geometry.
- the needle comprises a hollow rigid tubing 1401 having a cylindrical wall defining a longitudinal passage.
- the cylindrical wall includes first and second opposing wall portions.
- First wall portion is illustrated in this figure by longitudinal cross-section 1404 and second wall portion is illustrated in this figure by longitudinal cross-section 1406 .
- the first wall portion 1404 has a forward tip portion 1408 terminating in a forward end tip 1410 .
- the second wall portion 1406 terminating at a position 1412 rearwardly spaced from the end tip 1408 .
- the forward tip portion 1408 is bent at angle 1414 .
- Angle 1414 is defined as the angle between tangent 1416 to curvature of the outer surface at the end tip 1410 and the longitudinal axis 1418 of needle 1400 .
- the forward end tip 1410 terminates in a region defined by an imaginary forward extrapolation of the thickness of second wall 1406 defined by limits 1422 and 1424 which are intended to insure that the end tip 1410 is always deflected far enough to always shield the lumen or opening 1420 , but not deflected so far to hinder the penetration or withdrawal of the needle (this applies equally to the embodiment of FIG. 17 ).
- Other C-tip geometry is the soft C-tip needle where the tip is deflected such that it is aligned with the cannula centerline or longitudinal axis 1418 . The soft C-tip geometry does not reduce coring as well as the hard C-tip geometry of needle 1400 of the present invention.
- the hard C-tip needle is manufactured according to the following process: Two-meter length of tubes are bundled and are cut to the cannula blank length. The ends of the tubes are de-burred and the tubes cleaned. The tubes are then automatically fed and automatically taped onto 18 inch grinding fixtures. The tubes on the grinding fixtures are placed on a grinding machine where a primary grind facet is applied. The tubes are then inclined and rotated to grind a second facet and inclined and rotated again to grind a third facet. The second and third facets are preferably symmetrical to one another. The cannula needle tip are rolled over to produce the curved hard “C” tip. The cannula are de-burred again and an anti-coring micro-blast is applied to the heel.
- the micro-blast may alternately be applied before bending.
- the cannula are electro or chemically polished then cleaned, dried, passivated and inspected before packaging.
- the cannula are packaged with the points/tips oriented in the same direction and wrapped in non-shedding paper to be placed in a polyethylene bag and into a foam line carton for distribution.
- FIG. 15 shows a sectional longitudinal view of a C-tip needle 1500 .
- Lancets 1502 are shown in relation to the primary bevel 1504 .
- a sectional transversal cut 16 of the tip 1508 is shown in FIG. 16 with a front ground where the tip 1508 is ground from the inside as shown on transversal cut 1600 .
- FIG. 17 shows a sectional longitudinal view of a C-tip needle 1700 .
- Lancets 1702 are shown in relation to the primary bevel 1704 .
- a sectional transversal cut 18 of the tip 1708 is shown in FIG. 18 with a back ground where the tip 1708 is ground from the outside as shown on transversal cut 1800 .
- Back-ground lancets bring advantages to a C-tip needle.
- An advantage is that the angled lancets may serve to further direct seal material away from the lumen.
- Another advantage is that the effectively narrower thus sharper leading edge may cut through clothing and skin or tissue more easily.
- the use of heavy-wall cannulas provides more wall thickness allowing a better optimization of the geometry of the back-ground lancets.
- FIG. 19 shows the consecutive transversal cross sectional views of the needle tip 1900 in a case of a Hard-C tip needle with a back ground geometry.
- the length of the needle is 1.343′′
- the inside diameter 1906 is between 0.0138 inch and 0.0154 inch
- the outside diameter 1908 is between 0.0280 and 0.0285.
- the tip 1900 is shown with consecutive transversal cross sectional views AA, BB, CC, DD, EE, FF, GG, MM displayed in FIGS. 19A , 19 B, 19 C, 19 D, 19 E, 19 F, 19 G and 19 M.
- FIG. 19A shows the transversal cut AA having the shape of a disc corresponding to the tube/cylindrical form of the needle.
- FIG. 19D shows the cross-section DD with the back grinds 1910 at an angle of 120° in relation to the base line 1912 .
- Other embodiments with a back grind with an angle of 130° are also within the scope of the present invention.
- FIG. 20 shows the consecutive transversal cross sectional views of the needle tip 2000 in a case of a Hard-C tip needle with a front ground geometry.
- the length of the needle is 1.343′′
- the inside diameter 2002 is between 0.0155 inch and 0.0170 inch
- the outside diameter 2004 is between 0.0280 and 0.0285.
- the tip 2000 is shown with consecutive transversal cross sectional views AA, BB, CC, DD, EE, FF, MM displayed in FIGS. 20A , 20 B, 20 C, 20 D, 20 E, 20 F, 20 M.
- FIG. 20A shows the transversal cut AA having the shape of a disc corresponding to the tube/cylindrical form of the needle, notice the cylindrical wall of the needle is thinner than in the previous embodiment.
- FIG. 20D shows cross-section DD with the front grinds 2010 at an angle of between about 25° and 35° and preferably 30° in relation to the base line 2015 .
- Tests show that the hard C-tip needle configuration can substantially eliminate coring when used in conjunction with softer springs that allow the tip of the needle to “flow” more easily inside the seal material.
- Combination of geometry elements for the C-tip such as back-ground geometry and hard C-tip configuration in conjunction with the use of softer springs, having a K spring constant between 1.5 lb/in and 6.5 lb/in, more preferably between 3 lb/in and 5 lb/in, provides enhanced performance of the needle in reducing coring.
- FIG. 21 shows a longitudinal sectional view of the needle tip 2100 coated with a conformal coating 2200 (shown in FIG. 22 ).
- a conformal coating is coating that conforms to the shape of the substrate while allowing blunting of sharp edges.
- conformal coating 2200 consists of a Parylene coating (shown in FIG. 22 ).
- Parylene is a registered trademark of polyparaxylylene coating, manufactured by Specialty Coating Systems, Inc. of Indianapolis, Ind. The application of Parylene in coating an injection device and needle is described in U.S. Pat. No. 5,354,286 which is incorporated herein by reference.
- FIG. 22 shows a close up view of needle heel 2102 .
- Membrane coring occurs when the needle heel 2102 cuts the outer surface of the seal. A rounded, or blunted, edge on the heel alleviates coring. Standard needles receive an abrasive blast during manufacturing however this blast is not sufficient since standard needles still create cores. Tests show that Parylene coating 2200 conforms well to the substrate geometry, including edges, for example edge 2202 , as shown in FIG. 22 .
- Parylene coating is applied at various thicknesses ranging from 0.0001 to 0.001 inch.
- Data collected in the study of effect of Parylene coating thickness on coring is summarized in graph shown in FIG. 23 .
- the graph particularly shows that Parylene coating overall decreases the likelihood of coring as well as decreases the size of the core.
- increasing the coating thickness beyond around 0.0005′′ does not help in decreasing coring but acts in the opposite manner by increasing coring.
- the graph in FIG. 23 clearly shows a curve minimum indicating that the optimum thickness of the coat accomplishing the desired results is a Parylene coating thickness around 0.0005′′.
- tests have shown that the use of a spring having a spring constant between 1.5 lb/inch and 6.5 lb/inch in conjunction with the use of a needle coated with Parylene is particularly beneficial in reducing coring.
- FIG. 24 shows a longitudinal sectional view of a cartridge assembly 2400 used in an automatic injector according to another embodiment of the present invention.
- Automatic injector uses an alternative mechanism for reducing the rate of acceleration of the needle thus slowing down the speed of the needle in comparison with prior art devices.
- the acceleration rate is reduced so that the speed of the needle is less than 680 inches/s when the needle pierces the seal.
- the reduction in acceleration rate is intended specifically to reduce the speed to a level at which coring will not occur.
- the speed at which the seal is pierced is also greater than 150 inches/s so that the injection operation is not delayed more than what is desirable.
- damping disk 2402 attached to needle 2404 is used to reduce the rate of acceleration of needle 2404 by the friction generated when disk 2402 flows inside liquid medicament 2406 .
- the flow resistance generated by the viscosity of the fluid liquid medicament against the movement of damping disk 2402 acts to reduce the rate of acceleration of needle 2404 . Therefore, similarly to the previous embodiments, the damping disk plays the role of friction for slowing the tip of the needle, hence ultimately to substantially eliminating coring.
- the Table below shows examples of geometries for various embodiments of the tip of the needle.
- the primary angle is selected between 13 to 18 degrees.
- the bend angle that is the angle between a tangent to a curvature of the outer surface of the end tip of the needle and a longitudinal axis of the needle, is selected to be between 51° and 100°, preferably between 85° and 95°, most preferably 90° ( FIG. 14 shows a bend angle of approximately 63° and FIG. 17 shows a bend angle of approximately 90°).
- the tip offset in relation to the wall of the needle is between 0.024 and 0.026 inches.
- the opening length is selected between 0.033 and 0.055 inches.
- the inside diameter is selected between 0.011 and 0.016 inches.
- the ratio length of opening to outside diameter of passage is between 1.7 to 2.2.
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
Description
- 1. Field of Invention
- The present invention relates to automatic injectors, and more particularly, to automatic injectors that reduce the likelihood of coring a sealing member.
- 2. Discussion of Related Art
- Automatic injectors are well known. Basically an automatic injector is a device for enabling an individual to self-administer, or administer to another, a dosage of a liquid medicament. An advantage of automatic injectors is that they contain a measured dosage of a liquid medicament in a sealed sterile condition capable of storage in such condition for an extensive period of non-use, during which period immediate injection of the stored dosage may be accomplished at any time under severe emergency conditions. Another advantage of automatic injectors is the administration of the self-contained dosage of liquid medicament is accomplished without the necessity of the user initially seeing the hypodermic needle through which the liquid medicament is injected or of manually penetrating such visible needle into the user's or another person's tissue.
- As stated above, automatic injectors are particularly suited for use under emergency conditions. For example many tens of millions of such automatic injectors have been manufactured and sold containing nerve gas antidotes for use under emergency chemical warfare conditions. Typical units which have been utilized for this purpose are disclosed in U.S. Pat. Nos. 2,832,339, 3,882,863, and 4,031,893. In addition units of this type have been manufactured and used in administering anti-arrhythmic medicaments under emergency conditions relating to hart attack medical situations. The use of an auto injector has also been proposed to provide other medicaments useful in treating heart attack symptoms such as clot selective thrombolic agents (for example, tPA) and related medicaments. See for example, U.S. Pat. Nos. 4,689,042, 4,755,169, and 4,795,433. In addition, automatic injectors have been widely marketed containing a dosage of epinephrine as an antidote for counteracting severe allergic reactions, as for example, to bee stings, and the like.
- In all of these instances, the auto-injector is specifically structured so that in its normal operation the needle extends into the tissue of the individual and a specified amount of liquid medicament stored in a cartridge within the injector is injected into the tissue of the individual.
- The hypodermic needle of an autoinjector has a forward end adapted to penetrate the clothing and flesh of an individual and a rearward end adapted to communicate with a liquid medicament source so that the medicament is permitted to flow from the source, through the central longitudinal bore or lumen in the needle, and into the flesh of the individual. In some embodiments, the needle is contained inside the cartridge containing the liquid medicament. For example one application exists in the field of automatic injection devices, wherein the liquid medicament is sealed within a tubular container or cartridge, generally made of glass, plastic or metal, having a rubber seal closing off at the forward end and a rubber plunger at the rearward end. For example see U.S. Pat. No. 5,354,286. During an injection operation, a stressed spring assembly is released moving a push rod against the plunger. The plunger pushes against the hub-end of the needle causing the needle to puncture the forward end seal of the cartridge and penetrates into the flesh of an individual. The liquid medicament is pushed at the same time through the needle, thus releasing the medicament into the individual's flesh.
- In another type of automatic injector, the needle is connected to the forward end of the cartridge. See U.S. Pat. No. 5,102,393. During an injection operation, the needle is forced through a resilient seal at the forward end of the outer housing or through an elongated rubber sheath surrounding the needle. In either case the needle is kept sterile by a seal disposed toward a forward end of the housing while the injector is stored. After the needle punctures the seal or sheath, it then is forced into the flesh of the individual.
- An issue that must be dealt with in each of the mentioned arrangements is that the forward end of the needle must perforate a rubber or other type of seal, and it is possible for the forward end of the needle to core out or dislodge a small particle of material from the seal and potentially block the needle orifice/lumen or be forced into the individual's flesh.
- To overcome these problems and others, it is proposed to provide an automatic injector in which the amount of coring by the needle is substantially reduced or eliminated.
- Therefore, in one embodiment of the present invention is to provide an automatic injector that comprises: a housing; a seal structure disposed toward a forward end of the housing; a cartridge contained within the housing; a charge of medicament contained in the cartridge; a plunger normally disposed in a generally rearward end of the cartridge and movable through the cartridge toward a generally forward end thereof in response to an actuating procedure. The movable plunger rearwardly confines said medicament within said cartridge. A needle is normally disposed within the housing, the needle being projectable from a forward end of said housing through said seal structure. The needle is communicable with the medicament so that movement of the plunger through the cartridge forces the medicament through the needle and into the flesh of an individual, in response to the predetermined actuating procedure. A releasable energy source is releasable in response to the predetermined actuating procedure to project the needle from the forward end of the housing and slidingly drive the plunger through the cartridge in sealed relation to expel the medicament through the needle and into the flesh of an individual. The cartridge has an increased friction region so as to slow the motion of the plunger as the forward end of the needle travels through the seal.
- In another embodiment, the needle carries a damping structure for reducing the rate of acceleration of the needle by the resistance created when said damping structure moves within said medicament.
- In addition, the present invention is directed to several automatic injection devices comprising novel needle structures that reduce coring of an elastic, plastic or rubber based structure at the forward end of the injector.
- These and other objects and advantages of the invention will become more apparent and more readily appreciated from the following detailed description of the presently preferred exemplary embodiments of the invention, taken in conjunction with the accompanying drawings, of which:
-
FIG. 1 is a longitudinal sectional view of an automatic injector according to an embodiment of the present invention; -
FIG. 2 is a longitudinal sectional view of a cartridge showing the friction region according to an embodiment of the present invention; -
FIG. 3 is a longitudinal sectional view of the cartridge showing the friction region according to an alternative embodiment of the present invention; -
FIG. 4 is a graph showing the force versus distance of travel of plunger in a configuration without an increased friction region, as will be described hereinafter; -
FIG. 5 is a graph showing the force versus distance of travel of plunger in a configuration when using embodiment illustrated inFIG. 3 ; -
FIG. 6 is a graph showing the force versus distance of travel of plunger in a configuration when using embodiment illustrated inFIG. 2 ; -
FIG. 7 is a graph showing the percentage of coring versus the inside diameter measured at an increased friction region, as will be described hereinafter; -
FIG. 8 is a graph showing the core length versus the inside diameter measured at an increased friction region, as will be described hereinafter; -
FIG. 9 is an enlarged view of a straight tip showing the point and the heel of the needle. -
FIG. 10 is a longitudinal sectional view of the hypodermic needle as installed in a cartridge according to another embodiment of the present invention; the hypodermic needle is shown having a curved tip; -
FIG. 11A is an enlargement of the tip of the needle according to embodiment illustrated inFIG. 10 having curved “C” tip; -
FIG. 11B is an enlargement frontal view of the pointed tip of the needle; -
FIG. 12 is a longitudinal expanded sectional view of the forward end of the needle showing the interaction of the seal material with a curved tip needle having a regular/thinner wall thickness; -
FIG. 13 is a longitudinal expanded sectional view of the forward end of the needle show the interaction of the seal material with a needle having a heavy/thicker wall thickness; -
FIG. 14 is a longitudinal expanded sectional view of the forward end of the needle showing the curvature tolerance limits; -
FIG. 15 is a longitudinal expanded sectional view of the forward end of the needle showing the front-ground geometry; -
FIG. 16 is a sectional transversal view of the forward end of the needle showing the front-ground geometry; -
FIG. 17 is a longitudinal expanded sectional view of the forward end of the needle showing the back-ground geometry; -
FIG. 18 is a sectional transversal view of the forward end of the needle showing the back-ground geometry; -
FIG. 19 shows the consecutive transversal sectional views of the forward end of the needle illustrating the back-ground geometry; -
FIG. 20 shows consecutive transversal sectional views of the forward end of the needle illustrating the front-ground geometry; -
FIG. 21 is a longitudinal view of the forward end of the needle according to an alternative embodiment of the present invention where Parylene coating is applied to the needle; -
FIG. 22 is a longitudinal expanded view of the heel of needle according to embodiment illustrated inFIG. 21 . The heel is shown uniformly coated with a conformal coating; -
FIG. 23 is a graph showing the percentage of coring and the coring mean length versus the coating thickness as applied in embodiment illustrated inFIG. 22 ; and -
FIG. 24 is a longitudinal sectional view of an automatic injector according to another embodiment of the present invention. - In the following description, for purposes of explanation and not limitation, specific details are set forth such as particular shapes and materials, mechanical components, techniques, etc. in order to facilitate a thorough understanding of the present invention. However, the invention may be practiced in other embodiments that depart from these specific details. The terms “damping structure”, “friction area”, “speed bump” and “narrowed diameter portion” are used interchangeably in this description to illustrate a feature that is used as a way to reduce the rate of acceleration thus decrease the speed at which the hypodermic needle punctures or pierces the forward seal in comparison with prior art auto-injectors. Also, for the purpose of this disclosure, the portions of the injector on the right side of
FIG. 1 (on the needle extension end) will be considered the front end, while the left side or activation end will be considered the rear end. - Referring, more particularly, to the drawings in detail, there is shown in
FIG. 1 anautomatic injector 100. Theautomatic injector 100 includes atubular housing 102, amedicament cartridge assembly 104, within the forward end portion of thehousing assembly 102, and areleasable energy source 106 which is releasable in response to a predetermined actuating procedure as will be described in detail in the following paragraphs. While the releasable energy source can be any type of assembly which effectuates an injection operation, such as a compressed gas assembly as disclosed in U.S. Pat. No. 4,518,384, it is preferred that the releasable energy source be a stressed spring assembly, as generally indicated at 106. The stressed spring assembly is disposed within the rearward end portion of thehousing assembly 102 in operative relation with themedicament cartridge assembly 104. A releasableend safety cap 108 positioned at the rear of thehousing assembly 102 is in operative relation with the stressedspring assembly 106. - The
housing assembly 102,medicament cartridge assembly 104, andstress spring assembly 106 are generally constructed in accordance with the teaching of U.S. Pat. No. 2,832,339, hereby incorporated by reference. As shown inFIG. 1 , thehousing assembly 102 includes a cylindricalouter housing member 110 having a centrally apertured cylindricalrear wall portion 112 of reduced diameter on which thesafety end cap 108 is mounted. Thehousing assembly 102 also includes an innercylindrical housing member 114 within thehousing member 110 within which is mounted themedicament cartridge assembly 104 and the stressedspring assembly 106. The forward portion of theinner housing member 114 is formed with a counterbore for receiving therein a cylindrical dosage container orcartridge 116 of themedicament cartridge assembly 104. The cartridge of the present invention is preferably made of metallic materials such as, but not limited to, stainless steel and aluminum. Other materials, such as plastic materials (eg., polypropylene) or glass are also within the scope of the present invention. - The forward end of the container or
cartridge 116 is closed by a stopper or seal 118, preferably, of suitable rubber or compliant plastic material. Thecartridge assembly 104 is retained in closing relation with the forward end of theinner housing member 114 by a housingend cap member 120 of molded plastic material. Thecap 120 is preferably retained on theinner housing member 114 by inter-engagement of a pair ofridges 122 formed on the exterior periphery of thetubular member 114 with anannular groove 124 formed on the interior periphery of thecap member 120. The rearward end of thecartridge 116 is closed by a rubber orplastic plunger 126 which is slidably, sealingly engaged with the inner surface ofcartridge 116 so as to enclose within the cartridge adosage 128 of a liquid medicament. - A
hypodermic needle 130 is disposed within thecartridge 116. It thus can be appreciated that thecartridge assembly 104 includescartridge 116,seal 118,needle 130 anddisc 132. As can be discerned fromFIG. 1 ,needle 130 is normally stored in contact with themedicament 128. However, in the broadest aspects of the present invention, it can be appreciated thatneedle 130 can be disposed in a separate chamber (either evacuated or filled with a preferably inert gas) forwardly of the medicament 128 (for example, see our U.S. Pat. Nos. 5,085,642 and 5,102,393), so long as the needle is somehow communicable with the medicament in a manner which permits the medicament to travel through the needle and into the flesh of an individual. The needle can also be disposed in contact with one of two medicaments, which are normally stored separately within the injector and then either mixed within the injector prior to an injection (e.g. see U.S. Pat. No. 5,041,088) or injected separately one after the other (see U.S. Pat. No. 5,092,843). Thehypodermic needle 130 is preferably made from stainless steel. - In the present embodiment, the
needle 130 has its pointed end disposed within a recess formed in theseal 118. Adisc 132 of plastic is disposed within the forward end of thecartridge 116 in surrounding, securing and guiding relation with thehypodermic needle 130 and in abutting engagement with theseal 118. Thedisc 132 serves to releasably hold the needle in its storage position to provide peripheral centering therefore during the dosage injecting stroke of theplunger 126. The rearward end of thehypodermic needle 130 is enlarged for engagement by the plunger and has aslot 134 formed in its side wall adjacent the enlarged end for communicating thedosage 128 with the hollow interior of thehypodermic needle 130 when theplunger 126 is in engagement therewith. Theinner housing member 114 is mounted within theouter housing member 110 for limited reciprocating movement as determined by a pair ofridges 136 formed on the exterior periphery of the tubularinner housing member 114 at a position spaced rearwardly from the pair ofridges 122. The pair ofridges 136 is adapted to engage with an elongatedannular groove 138 formed on the interior periphery of theouter housing member 110. - The stressed
spring assembly 106 includes a normally compressed butreleasable coil spring 142 and anelongated collet member 140. The collet member is disposed within the rearward portion of thehousing member 114 and has its forward end disposed adjacent to theplunger 126. The forward end of thecollet member 140 has aflange 141 configured to engage the forward end of the stressedcoil spring 142, which surrounds the central portion of theelongated collet member 140. Thecollet 140 has its rearward end engaged with alocking ring 152 sitting on anannular end flange 144 formed integrally on the rearward end of theinner housing member 114. - The rearward end of the
elongated collet member 140 are split to provide a plurality (e.g., four)flexible spring fingers 146, the rearward extremities of which are formed with rearwardly and outwardly facing cam releasing surfaces 148. Extending inwardly from the rearward end of eachcam surface 148 is locking shoulder 150 adapted to engage alocking ring 152 seated on the rear surface offlange 144. The forward portion of the aperturedcylindrical wall portion 112 is formed with acomplementary cam surface 154, which is disposed in engagement with the cam surfaces 148 so as to effect a laterally inward movement of thespring fingers 146 toward one another to disengage locking shoulders 150 from lockingring 152 in response to a relative forward actuating movement of theouter housing member 110 with respect to theinner housing member 114. This inward action of thespring fingers 146 is permitted only after thesafety cap 108 is removed, as will be described. - The operation of the injector will now be described. In the first step of operation,
releasable end cap 108 is removed from theinjector 100. This removal is accomplished simply by gripping the exterior periphery of theend cap 108 and moving it rearwardly while gripping and holding theouter housing member 110. Thecap member 108 carries with it asafety pin portion 160. With thesafety pin portion 160 removed from its safety position, which normally prevents the laterally inward movement of thespring fingers 146, the user can now complete the operation by moving theforward cap member 120 into contact with the tissue of a person to be injected. By applying a continued forward force on the exterior periphery of theouter housing member 110, cam surfaces 154 thereof are moved forwardly. This forward movement in cooperation with the cam surfaces 148 on thespring fingers 146 causes the locking surfaces 150 of the latter to move inwardly off of thelocking ring 152, thus releasing the stressedspring 142. Thespring 142 acts through thecollet member 140 to move the same forwardly which has the effect of moving theplunger 126 with it. As the plunger moves forwardly, it carries with it theneedle 130. The pointed forward end of the needle pierces through theseal 118 and into the tissue of the patient. At the same time, thedosage 128 of liquid medicament within thecartridge 116 is caused to move inwardly into theslot 134 of the needle and outwardly of the pointed forward end thereof as the same moves into the tissue of the user. - Referring more particularly to
FIG. 2A , describing in more detail thecartridge assembly 104. Thehypodermic needle 202 comprises an elongated tube, generally cylindrical terminated at the rearward end byhub 206. The forward end of the needle has a pointedshape 208, shown in more detail in enlargedFIG. 2B . Theneedle 202 is maintained along a longitudinal axis X withholder 210.Needle 202 is shown housed insidecartridge 212, containing a liquid medicament. However as stated previously needle 202 need not beinside cartridge 212 but can be arranged to be outside the medicament cartridge. The forward end ofcartridge 212 is terminated byseal 214 to keep the liquid medicament from leaking, shown in more detail onFIG. 2B . Thepointed end 208 ofneedle 202 is oriented towardseal 214. Therefore, initially theneedle 202 is disposed betweenplunger 204 andseal 214. The plunger is shown in this figure as a one piece material, however it is understood that the plunger can be made of a plurality of pieces with various ductile constants such as a harder piece and a softer piece of rubber. -
Seal 214 is made of a flexible material, such as but not limited to, rubber. It is known that polymers behave in a ductile manner when strained at low speed and behave in a brittle manner when strained at high speed. - In order to substantially reduce or eliminate coring, the
needle 202 is arranged to penetrate in a “gentle” manner into therubber seal 214 by reducing the thrust of the needle.Cartridge 104 has afriction region 215 for slowing the motion ofplunger 204 thus reducing the rate of acceleration ofneedle 202 when perforatingseal 214. The acceleration rate is reduced so that the speed of the needle is less than 680 inches/s when the needle pierces the seal. The reduction in acceleration rate is intended specifically to reduce the speed to a level at which coring will not occur. Preferably, the speed at which the seal is pierced is also greater than 150 inches/s so that the injection operation is not delayed more than what is desirable. The friction region in this embodiment is a narrowed diameter portion or localized narroweddiameter portion 222 in thewall 224 ofcartridge 212. The narroweddiameter portion 222 also referred to as speed bump is arranged betweenseal 214 andplunger 204. The narroweddiameter portion 222 is arranged and configured to reduce acceleration ofplunger 204, thus reducing the speed at which theneedle 202 would otherwise travel when theneedle tip 208 travels throughseal 214. The narroweddiameter portion 222 is created on the wall of thecartridge 212 with a pressure forming method, for example with a clamshell die. The die or a rolling process can be used to imprint a selected shape to the stainless wall ofcartridge 212. For example cylindrical rounded narrowed diameter portion around the cylindrical wall of the cartridge can be imprinted. - The localized narrowed
diameter portion 222 in thewall 224 ofcartridge 212 acts as a “speed bump” by slowing down the motion ofplunger 204. Indeed, the narroweddiameter portion 222 increases the normal force between the plunger periphery and thewall 224 ofcartridge 212, thus creating a frictional force counter to the plunger's movement. The narroweddiameter portion 222 increases the diametrical interference thereby increasing the friction and retardingplunger 204 movement. This slowed movement causes theneedle 202 to strain theseal 214 in a more ductile mode, thus leading to a substantial reduction in coring. - The speed bump is arranged to be only effective along a partial length of the
cartridge 212. This allows the plunger to receive the full spring force at the beginning of operation helping to overcome static friction between theplunger 204 and thecartridge 212. The speed bump then takes effect immediately prior to the front end of the needle contacts theseal 214. After theneedle tip 208 completes its penetration of theseal 214, the speed bump disengages making the full spring force available to ensure completeness of the injection process. - The
plunger 204 meets increased resistance when theplunger 204 reaches the narroweddiameter portion 222.Plunger 204 has a plurality ofribs 230 as shown inFIG. 2C . Each time arib 230 of theplunger 204 encounters an edge of narroweddiameter portion 222 the friction force is increased thus leading to a net decrease in injection acceleration rate. - In another embodiment, illustrated in
FIG. 3A , thefriction region 300 comprises a corrugated configuration comprising a plurality ofprojections 302, shown enlarged inFIG. 3B , in order to multiply the interference with theplunger 304. - It is to be understood however, that
friction region 300 can be any structure of the cartridge that slowsplunger 304. While in the embodiments shown it is the wall of the cartridge itself that performs this function, it should be appreciated that the cartridge may employ a separate structure inserted therein. Theplunger 304 meets increased resistance when the plunger's leading rib crosses the friction region leading edge. The rippled shape offriction region 300 illustrated inFIG. 3 exchanges some of the aforementioned diameter decrease in the previous embodiment in exchange for a multitude of leading edges. - To demonstrate the effectiveness of the present invention in substantially reducing formation of cores, a series of tests are implemented and data is acquired.
-
FIG. 4 shows the force-distance data profile of a standard cartridge-plunger. Thecurve 400 exhibits a highstatic friction spike 402 followed by a constantkinetic friction stage 404. Numerous tests are run to collect statistical data. The mean kinetic friction from the statistical data is determined to be 0.54 lb. The nearlyvertical spike 406 at the terminus represents bottoming of the plunger against the seal. -
FIG. 5 shows the force-distance data profile of a cartridge having corrugated portion and a plunger, as illustrated inFIG. 3 . The portion of travel in which the ripples are in effect is clearly visible oncurve 500. The “spikiness” of data at thefriction phase 502 is caused by the individual matings and separations of the individual ripples with plunger ribs. Similarly statistical data is acquired to allow calculation of the mean kinetic friction during the speed bump phase. The mean kinetic friction is determined to be 1.47 lb. The mean kinetic friction of the post speed bump phase, shown onFIG. 5 asphase 504, is 0.52 lb. -
FIG. 6 shows the force-distance data profile 600 of a smooth speed bump and a plunger having three ribs, as illustrated inFIG. 2 . The three largeconsecutive spikes 602 are caused by the three ribs of the plunger entering the speed bump. Thesmaller spikes 604 occur as the plunger's ribs exit the speed bump. Similarly statistical data is acquired to allow calculation of the mean kinetic friction during the speed bump phase. The mean kinetic friction during the speed bump phase is determined to be 1.71 lb. The mean kinetic friction of the post-speed bump phase, shown onFIG. 6 asphase 606, is similar to the data described previously. - Data is also acquired to demonstrate that the introduction of the speed bump reduces coring.
FIG. 7 shows the coring frequency versus the inside diameter of the cartridge at the speed bump. The highest point on the curve corresponds to the inside diameter 0.298″ of the cartridge without a speed bump. At this size (without a speed bump) approximately 70% of units tested produced cores. The lowest point on the curve corresponds to the smooth (without ridges) speed bump in its intended diameter of 0.278″. Statistical data showed a population of less than 1% revealed coring. - In the case of a cartridge with a speed bump, a softer spring for pushing the plunger, may be used if desired to allow a smoother transition from the diameter of cartridge without the bump to the diameter of the cartridge at the bump.
- In addition to coring frequency, the diameter of the particles generated by coring are also measured and reported in
FIG. 8 . As seen inFIG. 8 , the dimension of the core (particle) decreases when the inside diameter of the cartridge at the speed bump decreases. Therefore, the speed bump has also an advantage in decreasing the size of the coring particles. - These tests are carried out for a straight tip needle such as shown in
FIG. 9 (which is a simplified view of the needle ofFIG. 3A ).Needle tip 900 has generally apoint 902 and aheel 904. As can be seen in the following embodiments the needle tip can have a curved shape instead of a straight shape as inFIG. 9 . -
FIG. 10 shows a longitudinal sectional view of the automatic injector with hypodermic needle according to another embodiment of the present invention. Thehypodermic needle 1000 is shown having acurved tip 1002. As mentioned previously, and now illustrated inFIG. 11A , the curvedleading edge 1002 ofneedle 1000 having a C-tip configuration pushes the material of theseal 1004 far enough away from theheel 1100 to prevent intimate contact. Thecurved arrow 1102 indicates the direction of flow of seal material relative to the movement of theneedle 1000. The arrow indicates in particular that the seal material flows around thecurved tip 1002. In other words, thecurved tip 1002 acts as a shield for the orifice orlumen 1104 ofneedle 1000, by blocking theseal material 1004 from penetrating through theorifice 1104. The extent to which the needle tip is curved over the orifice influences seal coring frequency. -
FIG. 11B shows an enlargement frontal view of the pointedtip 1110 of the needle. Thecurved forward tip 1114 is shown completely shieldinglumen 1112 thus protectinglumen 1112 of being in direct contact with the seal material as previously discussed. In other words, thebent tip 1114 shields the entire cross-section of the longitudinal passage in the needle. -
FIG. 12 shows the interaction ofseal material 1200 withneedle 1202 having a regular wall thickness, preferably between 0.0055 inch and 0.0065 inch.FIG. 13 show the interaction ofseal material 1300 withneedle 1302 having a thicker wall (heavy wall) preferably between 0.0083 inch and 0.0090 inch. In particular,FIG. 13 illustrates that in the case of needle withheavy wall thickness 1302, theheel 1304 is further away from theseal material 1300, thus further reducing coring potential compared to needle withregular wall thickness 1202. Testing shows that in the eventuality cores are produced, cores are generally smaller when using heavy-wall needles versus regular wall needles of similar geometry. -
FIG. 14 shows the geometry of the C-tip needle 1400 with manufacturing limits for the hard C-tip geometry. The needle comprises a hollowrigid tubing 1401 having a cylindrical wall defining a longitudinal passage. The cylindrical wall includes first and second opposing wall portions. First wall portion is illustrated in this figure bylongitudinal cross-section 1404 and second wall portion is illustrated in this figure bylongitudinal cross-section 1406. Thefirst wall portion 1404 has aforward tip portion 1408 terminating in aforward end tip 1410. Thesecond wall portion 1406 terminating at a position 1412 rearwardly spaced from theend tip 1408. Theforward tip portion 1408 is bent atangle 1414.Angle 1414 is defined as the angle between tangent 1416 to curvature of the outer surface at theend tip 1410 and thelongitudinal axis 1418 ofneedle 1400. In one embodiment, theforward end tip 1410 terminates in a region defined by an imaginary forward extrapolation of the thickness ofsecond wall 1406 defined bylimits end tip 1410 is always deflected far enough to always shield the lumen oropening 1420, but not deflected so far to hinder the penetration or withdrawal of the needle (this applies equally to the embodiment ofFIG. 17 ). Other C-tip geometry is the soft C-tip needle where the tip is deflected such that it is aligned with the cannula centerline orlongitudinal axis 1418. The soft C-tip geometry does not reduce coring as well as the hard C-tip geometry ofneedle 1400 of the present invention. - The hard C-tip needle is manufactured according to the following process: Two-meter length of tubes are bundled and are cut to the cannula blank length. The ends of the tubes are de-burred and the tubes cleaned. The tubes are then automatically fed and automatically taped onto 18 inch grinding fixtures. The tubes on the grinding fixtures are placed on a grinding machine where a primary grind facet is applied. The tubes are then inclined and rotated to grind a second facet and inclined and rotated again to grind a third facet. The second and third facets are preferably symmetrical to one another. The cannula needle tip are rolled over to produce the curved hard “C” tip. The cannula are de-burred again and an anti-coring micro-blast is applied to the heel. The micro-blast may alternately be applied before bending. The cannula are electro or chemically polished then cleaned, dried, passivated and inspected before packaging. The cannula are packaged with the points/tips oriented in the same direction and wrapped in non-shedding paper to be placed in a polyethylene bag and into a foam line carton for distribution.
- All hypodermic needles have primary and secondary facets. The secondary facets are called lancets.
FIG. 15 shows a sectional longitudinal view of a C-tip needle 1500. Lancets 1502 are shown in relation to theprimary bevel 1504. A sectional transversal cut 16 of thetip 1508 is shown inFIG. 16 with a front ground where thetip 1508 is ground from the inside as shown ontransversal cut 1600.FIG. 17 shows a sectional longitudinal view of a C-tip needle 1700. Lancets 1702 are shown in relation to theprimary bevel 1704. A sectional transversal cut 18 of thetip 1708 is shown inFIG. 18 with a back ground where thetip 1708 is ground from the outside as shown ontransversal cut 1800. Back-ground lancets bring advantages to a C-tip needle. An advantage is that the angled lancets may serve to further direct seal material away from the lumen. Another advantage is that the effectively narrower thus sharper leading edge may cut through clothing and skin or tissue more easily. The use of heavy-wall cannulas provides more wall thickness allowing a better optimization of the geometry of the back-ground lancets. -
FIG. 19 shows the consecutive transversal cross sectional views of theneedle tip 1900 in a case of a Hard-C tip needle with a back ground geometry. In one embodiment, the length of the needle is 1.343″, theinside diameter 1906 is between 0.0138 inch and 0.0154 inch and theoutside diameter 1908 is between 0.0280 and 0.0285. Thetip 1900 is shown with consecutive transversal cross sectional views AA, BB, CC, DD, EE, FF, GG, MM displayed inFIGS. 19A , 19B, 19C, 19D, 19E, 19F, 19G and 19M.FIG. 19A shows the transversal cut AA having the shape of a disc corresponding to the tube/cylindrical form of the needle. Further along approaching the tip of the needle,FIG. 19D shows the cross-section DD with the back grinds 1910 at an angle of 120° in relation to thebase line 1912. Other embodiments with a back grind with an angle of 130° are also within the scope of the present invention. -
FIG. 20 shows the consecutive transversal cross sectional views of theneedle tip 2000 in a case of a Hard-C tip needle with a front ground geometry. In one embodiment, the length of the needle is 1.343″, theinside diameter 2002 is between 0.0155 inch and 0.0170 inch and theoutside diameter 2004 is between 0.0280 and 0.0285. Thetip 2000 is shown with consecutive transversal cross sectional views AA, BB, CC, DD, EE, FF, MM displayed inFIGS. 20A , 20B, 20C, 20D, 20E, 20F, 20M.FIG. 20A shows the transversal cut AA having the shape of a disc corresponding to the tube/cylindrical form of the needle, notice the cylindrical wall of the needle is thinner than in the previous embodiment. Further along approaching the tip of the needle,FIG. 20D shows cross-section DD with the front grinds 2010 at an angle of between about 25° and 35° and preferably 30° in relation to thebase line 2015. - Tests show that the hard C-tip needle configuration can substantially eliminate coring when used in conjunction with softer springs that allow the tip of the needle to “flow” more easily inside the seal material. Combination of geometry elements for the C-tip such as back-ground geometry and hard C-tip configuration in conjunction with the use of softer springs, having a K spring constant between 1.5 lb/in and 6.5 lb/in, more preferably between 3 lb/in and 5 lb/in, provides enhanced performance of the needle in reducing coring.
-
FIG. 21 shows a longitudinal sectional view of theneedle tip 2100 coated with a conformal coating 2200 (shown inFIG. 22 ). A conformal coating is coating that conforms to the shape of the substrate while allowing blunting of sharp edges. In one embodiment,conformal coating 2200 consists of a Parylene coating (shown inFIG. 22 ). Parylene is a registered trademark of polyparaxylylene coating, manufactured by Specialty Coating Systems, Inc. of Indianapolis, Ind. The application of Parylene in coating an injection device and needle is described in U.S. Pat. No. 5,354,286 which is incorporated herein by reference.FIG. 22 shows a close up view ofneedle heel 2102. Membrane coring occurs when theneedle heel 2102 cuts the outer surface of the seal. A rounded, or blunted, edge on the heel alleviates coring. Standard needles receive an abrasive blast during manufacturing however this blast is not sufficient since standard needles still create cores. Tests show thatParylene coating 2200 conforms well to the substrate geometry, including edges, forexample edge 2202, as shown inFIG. 22 . - Parylene coating is applied at various thicknesses ranging from 0.0001 to 0.001 inch. Data collected in the study of effect of Parylene coating thickness on coring is summarized in graph shown in
FIG. 23 . The graph particularly shows that Parylene coating overall decreases the likelihood of coring as well as decreases the size of the core. However, as seen on the graph, increasing the coating thickness beyond around 0.0005″ does not help in decreasing coring but acts in the opposite manner by increasing coring. Indeed, the graph inFIG. 23 clearly shows a curve minimum indicating that the optimum thickness of the coat accomplishing the desired results is a Parylene coating thickness around 0.0005″. In addition, tests have shown that the use of a spring having a spring constant between 1.5 lb/inch and 6.5 lb/inch in conjunction with the use of a needle coated with Parylene is particularly beneficial in reducing coring. -
FIG. 24 shows a longitudinal sectional view of acartridge assembly 2400 used in an automatic injector according to another embodiment of the present invention. Automatic injector uses an alternative mechanism for reducing the rate of acceleration of the needle thus slowing down the speed of the needle in comparison with prior art devices. The acceleration rate is reduced so that the speed of the needle is less than 680 inches/s when the needle pierces the seal. The reduction in acceleration rate is intended specifically to reduce the speed to a level at which coring will not occur. Preferably, the speed at which the seal is pierced is also greater than 150 inches/s so that the injection operation is not delayed more than what is desirable. Indeed, dampingdisk 2402 attached toneedle 2404 is used to reduce the rate of acceleration ofneedle 2404 by the friction generated whendisk 2402 flows insideliquid medicament 2406. In other words, the flow resistance generated by the viscosity of the fluid liquid medicament against the movement of dampingdisk 2402 acts to reduce the rate of acceleration ofneedle 2404. Therefore, similarly to the previous embodiments, the damping disk plays the role of friction for slowing the tip of the needle, hence ultimately to substantially eliminating coring. - The Table below shows examples of geometries for various embodiments of the tip of the needle. The primary angle is selected between 13 to 18 degrees. The bend angle, that is the angle between a tangent to a curvature of the outer surface of the end tip of the needle and a longitudinal axis of the needle, is selected to be between 51° and 100°, preferably between 85° and 95°, most preferably 90° (
FIG. 14 shows a bend angle of approximately 63° andFIG. 17 shows a bend angle of approximately 90°). The tip offset in relation to the wall of the needle is between 0.024 and 0.026 inches. The opening length is selected between 0.033 and 0.055 inches. The inside diameter is selected between 0.011 and 0.016 inches. The ratio length of opening to outside diameter of passage is between 1.7 to 2.2. -
Primary Bend Angle Opening Inside Angle (tangent @ tip) Length Diameter Ratio, Tip Offset (deg) (deg) (in) (in) L/OD (in) 10010 (Hard-C) 14 63, 81 .061 .016 2.2 .026 10014 (HC, Heavy Wall) 13 51, 81 .049 .015 1.7 .024 10017 (HC, HW, Back Ground) 16.5 90, 90 .063 .015 1.9 .024 10018 (HC, HW, BG, B-tip) 13 90 .053 .011 1.9 .024 - While the invention has been described in connection with particular embodiments, it is to be understood that the invention is not limited to the disclosed embodiments, but on the contrary it is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the invention as defined by the claims, which follow.
Claims (39)
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/985,466 US7569035B1 (en) | 2001-11-02 | 2001-11-02 | Automatic injector with anti-coring needle |
KR1020047006620A KR20050043735A (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle |
JP2003541922A JP2005508232A (en) | 2001-11-02 | 2002-11-04 | Automatic syringe with centering prevention needle |
EP05024798A EP1627652A3 (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle |
ES02773966T ES2281544T3 (en) | 2001-11-02 | 2002-11-04 | AUTOMATIC INJECTOR WITH ANTI-ENUCLEATION NEEDLE. |
CNB02825130XA CN100406076C (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle |
MXPA04004161A MXPA04004161A (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle. |
AT02773966T ATE352335T1 (en) | 2001-11-02 | 2002-11-04 | AUTOMATIC SYRINGE WITH A NEEDLE THAT DOES NOT PUNCH A CORE |
CA2465443A CA2465443C (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle |
PCT/US2002/035215 WO2003039633A2 (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle |
DE60217892T DE60217892T2 (en) | 2001-11-02 | 2002-11-04 | AUTOMATIC SYRINGE WITH A NEEDLE THAT DOES NOT PUT A CORE |
EP05024799A EP1627653A3 (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle |
EP02773966A EP1441786B1 (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle |
AU2002336714A AU2002336714B2 (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle |
DK02773966T DK1441786T3 (en) | 2001-11-02 | 2002-11-04 | Automatic injector with an anti-cutout needle |
IL16168102A IL161681A0 (en) | 2001-11-02 | 2002-11-04 | Automatic injector with anti-coring needle |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/985,466 US7569035B1 (en) | 2001-11-02 | 2001-11-02 | Automatic injector with anti-coring needle |
Publications (2)
Publication Number | Publication Date |
---|---|
US20090192486A1 true US20090192486A1 (en) | 2009-07-30 |
US7569035B1 US7569035B1 (en) | 2009-08-04 |
Family
ID=25531514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/985,466 Active 2026-05-03 US7569035B1 (en) | 2001-11-02 | 2001-11-02 | Automatic injector with anti-coring needle |
Country Status (14)
Country | Link |
---|---|
US (1) | US7569035B1 (en) |
EP (3) | EP1441786B1 (en) |
JP (1) | JP2005508232A (en) |
KR (1) | KR20050043735A (en) |
CN (1) | CN100406076C (en) |
AT (1) | ATE352335T1 (en) |
AU (1) | AU2002336714B2 (en) |
CA (1) | CA2465443C (en) |
DE (1) | DE60217892T2 (en) |
DK (1) | DK1441786T3 (en) |
ES (1) | ES2281544T3 (en) |
IL (1) | IL161681A0 (en) |
MX (1) | MXPA04004161A (en) |
WO (1) | WO2003039633A2 (en) |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100185178A1 (en) * | 2009-01-20 | 2010-07-22 | Robert Sharp | Injection device |
US20110092917A1 (en) * | 2008-05-05 | 2011-04-21 | Becton, Dickinson And Company | Drug delivery device having cartridge with enlarged distal end |
US20110172636A1 (en) * | 2007-08-17 | 2011-07-14 | Aasmul Soeren | Injection apparatus and special needle for making an injection at a predetermined depth in the skin |
US8313466B2 (en) | 2004-11-22 | 2012-11-20 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US8361029B2 (en) | 2004-11-22 | 2013-01-29 | Intelliject, Llc | Devices, systems and methods for medicament delivery |
US8425462B2 (en) | 2004-11-22 | 2013-04-23 | Intelliject, Inc. | Devices, systems, and methods for medicament delivery |
US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9022022B2 (en) | 2011-02-28 | 2015-05-05 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9056170B2 (en) | 2004-11-22 | 2015-06-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US20150174337A1 (en) * | 2013-03-26 | 2015-06-25 | Terumo Kabushiki Kaisha | Elastic cap and syringe assembly therewith |
US9084849B2 (en) | 2011-01-26 | 2015-07-21 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
CN105169534A (en) * | 2015-08-10 | 2015-12-23 | 苏州灵岩医疗科技股份有限公司 | Needle tip for injection |
US20160051981A1 (en) * | 2012-07-23 | 2016-02-25 | Tasso, Inc. | Methods, Systems, and Devices Relating to Open Microfluidic Channels |
US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
US9931472B2 (en) | 2012-04-17 | 2018-04-03 | Universiteit Antwerpen | Intradermal injection device |
US10071203B2 (en) | 2004-11-22 | 2018-09-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US10576206B2 (en) | 2015-06-30 | 2020-03-03 | Kaleo, Inc. | Auto-injectors for administration of a medicament within a prefilled syringe |
US10688244B2 (en) | 2016-12-23 | 2020-06-23 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
US10737028B2 (en) | 2004-11-22 | 2020-08-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US11033212B2 (en) | 2014-08-01 | 2021-06-15 | Tasso, Inc. | Devices, systems and methods for gravity-enhanced microfluidic collection, handling and transferring of fluids |
US11167087B2 (en) | 2019-08-09 | 2021-11-09 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
US11395614B2 (en) | 2012-01-25 | 2022-07-26 | Tasso, Inc. | Methods, systems, and devices relating to open microfluidic channels |
US11413405B2 (en) | 2016-04-01 | 2022-08-16 | Idevax Bv | Injection device |
US11510659B2 (en) | 2018-09-14 | 2022-11-29 | Tasso, Inc. | Bodily fluid collection devices and related methods |
US11590286B2 (en) | 2004-11-22 | 2023-02-28 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US11642057B2 (en) | 2015-12-21 | 2023-05-09 | Tasso, Inc. | Devices, systems and methods for actuation and retraction in fluid collection |
US12048836B2 (en) | 2018-04-19 | 2024-07-30 | Sanofi | Force reduction in injection devices |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003209095A1 (en) | 2002-02-11 | 2003-09-04 | Antares Pharma, Inc. | Intradermal injector |
IL157981A (en) | 2003-09-17 | 2014-01-30 | Elcam Medical Agricultural Cooperative Ass Ltd | Auto-injector |
GB2414775B (en) | 2004-05-28 | 2008-05-21 | Cilag Ag Int | Releasable coupling and injection device |
GB2414403B (en) | 2004-05-28 | 2009-01-07 | Cilag Ag Int | Injection device |
GB2414402B (en) | 2004-05-28 | 2009-04-22 | Cilag Ag Int | Injection device |
GB2414400B (en) | 2004-05-28 | 2009-01-14 | Cilag Ag Int | Injection device |
GB2414399B (en) | 2004-05-28 | 2008-12-31 | Cilag Ag Int | Injection device |
GB2414404B (en) | 2004-05-28 | 2009-06-03 | Cilag Ag Int | Injection device |
GB2414406B (en) | 2004-05-28 | 2009-03-18 | Cilag Ag Int | Injection device |
GB2414405B (en) | 2004-05-28 | 2009-01-14 | Cilag Ag Int | Injection device |
GB2414409B (en) | 2004-05-28 | 2009-11-18 | Cilag Ag Int | Injection device |
GB0414054D0 (en) | 2004-06-23 | 2004-07-28 | Owen Mumford Ltd | Improvements relating to automatic injection devices |
US7449012B2 (en) | 2004-08-06 | 2008-11-11 | Meridian Medical Technologies, Inc. | Automatic injector |
DK1850892T4 (en) | 2005-01-24 | 2023-06-06 | Antares Pharma Inc | Prefilled needle-assisted syringe injector |
GB2424836B (en) | 2005-04-06 | 2010-09-22 | Cilag Ag Int | Injection device (bayonet cap removal) |
GB2425062B (en) | 2005-04-06 | 2010-07-21 | Cilag Ag Int | Injection device |
GB2427826B (en) | 2005-04-06 | 2010-08-25 | Cilag Ag Int | Injection device comprising a locking mechanism associated with integrally formed biasing means |
PL1759729T3 (en) | 2005-08-30 | 2010-09-30 | Cilag Gmbh Int | Needle assembly for a prefilled syringe system |
US20110098656A1 (en) | 2005-09-27 | 2011-04-28 | Burnell Rosie L | Auto-injection device with needle protecting cap having outer and inner sleeves |
US20070202186A1 (en) | 2006-02-22 | 2007-08-30 | Iscience Interventional Corporation | Apparatus and formulations for suprachoroidal drug delivery |
US8197435B2 (en) | 2006-05-02 | 2012-06-12 | Emory University | Methods and devices for drug delivery to ocular tissue using microneedle |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
US8251947B2 (en) | 2006-05-03 | 2012-08-28 | Antares Pharma, Inc. | Two-stage reconstituting injector |
GB2438593B (en) | 2006-06-01 | 2011-03-30 | Cilag Gmbh Int | Injection device (cap removal feature) |
GB2438590B (en) | 2006-06-01 | 2011-02-09 | Cilag Gmbh Int | Injection device |
GB2438591B (en) | 2006-06-01 | 2011-07-13 | Cilag Gmbh Int | Injection device |
BRPI0713802A2 (en) * | 2006-06-30 | 2012-11-06 | Abbott Biotech Ltd | automatic injection device |
US9345831B2 (en) * | 2006-10-19 | 2016-05-24 | E3D Agricultural Cooperative Association Ltd | Automatic injection device |
EP2268342B1 (en) | 2008-03-10 | 2015-09-16 | Antares Pharma, Inc. | Injector safety device |
GB2461086B (en) | 2008-06-19 | 2012-12-05 | Cilag Gmbh Int | Injection device |
GB2461089B (en) | 2008-06-19 | 2012-09-19 | Cilag Gmbh Int | Injection device |
GB2461085B (en) | 2008-06-19 | 2012-08-29 | Cilag Gmbh Int | Injection device |
GB2461087B (en) | 2008-06-19 | 2012-09-26 | Cilag Gmbh Int | Injection device |
GB2461084B (en) | 2008-06-19 | 2012-09-26 | Cilag Gmbh Int | Fluid transfer assembly |
US8376993B2 (en) | 2008-08-05 | 2013-02-19 | Antares Pharma, Inc. | Multiple dosage injector |
UA104301C2 (en) * | 2008-11-25 | 2014-01-27 | Ритректебл Текнолоджиз, Инк. | Glass cylinder with retractable needle |
EP2251453B1 (en) | 2009-05-13 | 2013-12-11 | SiO2 Medical Products, Inc. | Vessel holder |
JP5732039B2 (en) | 2009-03-20 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | Hazardous drug injection system |
WO2010127146A1 (en) | 2009-04-29 | 2010-11-04 | Abbott Biotechnology Ltd | Automatic injection device |
WO2013170052A1 (en) | 2012-05-09 | 2013-11-14 | Sio2 Medical Products, Inc. | Saccharide protective coating for pharmaceutical package |
US9458536B2 (en) | 2009-07-02 | 2016-10-04 | Sio2 Medical Products, Inc. | PECVD coating methods for capped syringes, cartridges and other articles |
TWI619521B (en) | 2009-12-15 | 2018-04-01 | 艾伯維生物技術有限責任公司 | Automatic injection device, automatic injection method and method for preventing misfiring |
RU2573042C2 (en) | 2010-04-21 | 2016-01-20 | Эббви Байотекнолоджи Лтд. | Worn device for automatic injection for controlled supply of therapeutic agents |
US11624115B2 (en) | 2010-05-12 | 2023-04-11 | Sio2 Medical Products, Inc. | Syringe with PECVD lubrication |
WO2011162686A1 (en) * | 2010-06-24 | 2011-12-29 | Shl Group Ab | Medicament delivery device with braking means |
EP3520749A1 (en) | 2010-10-15 | 2019-08-07 | Clearside Biomedical, Inc. | Device for ocular access |
US9878101B2 (en) | 2010-11-12 | 2018-01-30 | Sio2 Medical Products, Inc. | Cyclic olefin polymer vessels and vessel coating methods |
US8992477B2 (en) | 2011-01-24 | 2015-03-31 | Elcam Agricultural Cooperative Association Ltd. | Injector |
UA115423C2 (en) | 2011-01-24 | 2017-11-10 | Еббі Байотекнолоджі Лтд. | AUTOMATIC INJECTION DEVICES WITH FORMED SURFACES |
AU2012209222B2 (en) | 2011-01-24 | 2015-07-09 | Abbvie Biotechnology Ltd | Removal of needle shields from syringes and automatic injection devices |
US9272095B2 (en) | 2011-04-01 | 2016-03-01 | Sio2 Medical Products, Inc. | Vessels, contact surfaces, and coating and inspection apparatus and methods |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
DE102011112021B4 (en) * | 2011-08-31 | 2013-10-24 | Hans Haindl | Puncture cannula |
US11116695B2 (en) | 2011-11-11 | 2021-09-14 | Sio2 Medical Products, Inc. | Blood sample collection tube |
US10189603B2 (en) | 2011-11-11 | 2019-01-29 | Sio2 Medical Products, Inc. | Passivation, pH protective or lubricity coating for pharmaceutical package, coating process and apparatus |
EP4327849A3 (en) | 2012-03-06 | 2024-04-24 | Antares Pharma, Inc. | Prefilled syringe with breakaway force feature |
US9950125B2 (en) | 2012-04-06 | 2018-04-24 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
WO2013169800A1 (en) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
JP6343840B2 (en) * | 2012-06-26 | 2018-06-20 | 株式会社ユニークメディカル | Injection needle and electrode needle |
WO2014017986A1 (en) * | 2012-07-26 | 2014-01-30 | Agency For Science, Technology And Research | Vascular access device and guiding portion |
EP2711080B1 (en) | 2012-09-24 | 2019-04-10 | Siemens Healthcare Diagnostics Products GmbH | Hollow needle for a sample pipettor |
EP2914762B1 (en) | 2012-11-01 | 2020-05-13 | SiO2 Medical Products, Inc. | Coating inspection method |
MX2015005839A (en) | 2012-11-08 | 2015-12-17 | Clearside Biomedical Inc | Methods and devices for the treatment of ocular diseases in human subjects. |
EP2920567B1 (en) | 2012-11-16 | 2020-08-19 | SiO2 Medical Products, Inc. | Method and apparatus for detecting rapid barrier coating integrity characteristics |
EP2925903B1 (en) | 2012-11-30 | 2022-04-13 | Si02 Medical Products, Inc. | Controlling the uniformity of pecvd deposition on medical syringes, cartridges, and the like |
US9764093B2 (en) | 2012-11-30 | 2017-09-19 | Sio2 Medical Products, Inc. | Controlling the uniformity of PECVD deposition |
PT2953667T (en) | 2013-02-11 | 2020-01-28 | Antares Pharma Inc | NEEDLE-ASSISTED JET INJECTION DEVICE WITH REDUCED TRIGGER STRENGTH |
EP2961858B1 (en) | 2013-03-01 | 2022-09-07 | Si02 Medical Products, Inc. | Coated syringe. |
US9937099B2 (en) | 2013-03-11 | 2018-04-10 | Sio2 Medical Products, Inc. | Trilayer coated pharmaceutical packaging with low oxygen transmission rate |
ES2742046T3 (en) | 2013-03-11 | 2020-02-12 | Antares Pharma Inc | Dose injector with pinion system |
KR102472240B1 (en) | 2013-03-11 | 2022-11-30 | 에스아이오2 메디컬 프로덕츠, 인크. | Coated Packaging |
WO2014165136A1 (en) | 2013-03-12 | 2014-10-09 | Antares Pharma, Inc. | Constant volume prefilled syringes and kits thereof |
EP2971227B1 (en) | 2013-03-15 | 2017-11-15 | Si02 Medical Products, Inc. | Coating method. |
AU2014259005B2 (en) * | 2013-04-23 | 2019-01-03 | E3D Agricultural Cooperative Association Ltd. | Automatic injection device for administration of high viscosity medication |
SG10201702674PA (en) | 2013-05-03 | 2017-06-29 | Clearside Biomedical Inc | Apparatus and methods for ocular injection |
US10188550B2 (en) | 2013-06-03 | 2019-01-29 | Clearside Biomedical, Inc. | Apparatus and methods for drug delivery using multiple reservoirs |
GB2515038A (en) | 2013-06-11 | 2014-12-17 | Cilag Gmbh Int | Injection device |
GB2515039B (en) | 2013-06-11 | 2015-05-27 | Cilag Gmbh Int | Injection Device |
GB2517896B (en) | 2013-06-11 | 2015-07-08 | Cilag Gmbh Int | Injection device |
GB2515032A (en) | 2013-06-11 | 2014-12-17 | Cilag Gmbh Int | Guide for an injection device |
EP3693493A1 (en) | 2014-03-28 | 2020-08-12 | SiO2 Medical Products, Inc. | Antistatic coatings for plastic vessels |
JP2017524419A (en) | 2014-06-20 | 2017-08-31 | クリアサイド バイオメディカル,インコーポレイテッド | Variable diameter cannula and method for controlling insertion depth for drug delivery |
USD750223S1 (en) | 2014-10-14 | 2016-02-23 | Clearside Biomedical, Inc. | Medical injector for ocular injection |
EP3240594B1 (en) | 2014-12-29 | 2024-04-03 | Novo Nordisk A/S | Drug delivery device with a hydraulic trigger mechanism |
CN116982977A (en) | 2015-08-18 | 2023-11-03 | Sio2医药产品公司 | Medicaments and other packages with low oxygen transmission rate |
WO2017139375A1 (en) | 2016-02-10 | 2017-08-17 | Clearside Biomedical, Inc. | Ocular injection kit, packaging, and methods of use |
CA3062845A1 (en) | 2016-05-02 | 2017-11-09 | Clearside Biomedical, Inc. | Systems and methods for ocular drug delivery |
WO2018031913A1 (en) | 2016-08-12 | 2018-02-15 | Clearside Biomedical, Inc. | Devices and methods for adjusting the insertion depth of a needle for medicament delivery |
WO2018204515A1 (en) | 2017-05-02 | 2018-11-08 | Georgia Tech Research Corporation | Targeted drug delivery methods using a microneedle |
WO2019144187A1 (en) * | 2018-01-24 | 2019-08-01 | M. Attalla Pty Ltd | Apparatus and method for injecting material into organic tissue |
Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US648858A (en) * | 1900-03-14 | 1900-05-01 | Charles B Dolge | Embalming-needle. |
US2590895A (en) * | 1949-11-21 | 1952-04-01 | Louis A Scarpellino | Myelographic needle |
US2634726A (en) * | 1952-01-30 | 1953-04-14 | Ralph D Hanson | Hypodermic needle |
US2711733A (en) * | 1951-08-10 | 1955-06-28 | Jr George W Jacoby | Hypodermic needle |
US2737948A (en) * | 1954-08-23 | 1956-03-13 | Pfizer & Co C | Disposable cartridge for hypodermic syringe |
US2745403A (en) * | 1954-10-14 | 1956-05-15 | Samuel D Goldberg | Disposable cartridge type syringe |
US2746454A (en) * | 1953-05-04 | 1956-05-22 | Hans W Sorensen | Intravenous needle |
US2748769A (en) * | 1953-02-24 | 1956-06-05 | Huber Jennie | Hypodermic needle |
US2936756A (en) * | 1955-07-01 | 1960-05-17 | Gabriel Daniel | Hypodermic needle unit for discharge of medications from pressurized vials |
US3492992A (en) * | 1969-03-26 | 1970-02-03 | Deknatel Inc | Hypodermic needle |
US3788119A (en) * | 1972-08-17 | 1974-01-29 | Baxter Laboratories Inc | Method of forming spinal needle |
US3924617A (en) * | 1973-09-28 | 1975-12-09 | Crinospital Spa | Aspiration and infusion needle |
US4381779A (en) * | 1981-07-16 | 1983-05-03 | Sterling Drug Inc. | Deformable slidable piston to provide self-aspiration in hypodermic cartridge ampoules |
US4394863A (en) * | 1981-10-23 | 1983-07-26 | Survival Technology, Inc. | Automatic injector with cartridge having separate sequentially injectable medicaments |
US4413993A (en) * | 1973-07-30 | 1983-11-08 | Guttman Yolan R | Infiltration-proof intravenous needle |
US4490139A (en) * | 1983-01-28 | 1984-12-25 | Eli Lilly And Company | Implant needle and method |
US4537593A (en) * | 1983-06-06 | 1985-08-27 | Becton, Dickinson And Co. | Self-venting, non-coring needle assembly |
US4661098A (en) * | 1982-10-27 | 1987-04-28 | Duphar International Research B.V. | Automatic injection device |
US4808170A (en) * | 1985-12-16 | 1989-02-28 | Alcon Laboratories, Inc. | Hypotraumatic injection needle useful in ophthalmic surgery |
US4826170A (en) * | 1987-02-23 | 1989-05-02 | Overman Enterprises Inc. | Liar's dice box |
US4889529A (en) * | 1987-07-10 | 1989-12-26 | B. Braun Melsungen Ag | Needle |
US4968302A (en) * | 1986-07-01 | 1990-11-06 | Eberhardt Schluter | Automatic injection device, including an ampoule or a cartridge for an injection device |
US4969877A (en) * | 1988-10-19 | 1990-11-13 | The Pascall Medical Corporation | Syringe |
US5102393A (en) * | 1989-07-17 | 1992-04-07 | Survival Technology, Inc. | Autoinjector converted from intramuscular to subcutaneous mode of injection |
US5290267A (en) * | 1991-01-17 | 1994-03-01 | Fresenius Ag | Hypodermic needle |
US5354286A (en) * | 1993-12-07 | 1994-10-11 | Survival Technology, Inc. | Injection device having polyparaxylylene coated container |
US5391151A (en) * | 1991-01-15 | 1995-02-21 | Survival Technology, Inc. | Subcutaneous injector |
US5533993A (en) * | 1994-10-05 | 1996-07-09 | International Medication Systems, Limited | Medication injector with protected cannula and Y-site lockout |
US5575780A (en) * | 1995-04-28 | 1996-11-19 | Saito; Yoshikuni | Medical hollow needle and a method of producing thereof |
US5709668A (en) * | 1991-01-16 | 1998-01-20 | Senetek Plc | Automatic medicament injector employing non-coring needle |
US5716348A (en) * | 1995-10-19 | 1998-02-10 | Meridian Medical Technologies, Inc. | Anti-coring needle |
US5820609A (en) * | 1995-04-28 | 1998-10-13 | Saito; Yoshikuni | Medical hollow needle and a method of producing thereof |
US5968022A (en) * | 1995-04-28 | 1999-10-19 | Saito; Yoshikuni | Medical hollow needle and method of production |
US6004300A (en) * | 1997-08-28 | 1999-12-21 | Butcher; Robert M | Composite hypodermic syringe piston |
US6213989B1 (en) * | 1995-07-28 | 2001-04-10 | Dsu Medical Corporation | Hypodermic cannula |
US6626887B1 (en) * | 1999-06-08 | 2003-09-30 | Intravantage, Inc. | Hard tissue drug delivery device and method |
US6702791B1 (en) * | 1999-02-04 | 2004-03-09 | Integ, Inc. | Needle for body fluid tester |
US7070583B1 (en) * | 2000-07-03 | 2006-07-04 | Dr. Japan Co., Ltd. | Medical bevel needle |
US20080154217A1 (en) * | 2005-02-03 | 2008-06-26 | Vygon | Puncture Tips And Catheter Tubes |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE531562A (en) * | 1953-09-02 | |||
FR1225009A (en) | 1959-02-11 | 1960-06-28 | Hypodermic or intravenous needle and its manufacturing process | |
US4826489A (en) | 1988-01-14 | 1989-05-02 | Habley Medical Technology Corporation | Disposable safety syringe having means for retracting its needle cannula into its medication cartridge |
AU1926792A (en) | 1991-05-13 | 1992-12-30 | Sti International Limited | Automatic injectors |
ATE138582T1 (en) * | 1992-03-27 | 1996-06-15 | Duphar Int Res | AUTOMATIC SYRINGE |
DE4226476C1 (en) | 1992-08-10 | 1993-08-12 | Hans Dr.Med. 3015 Wennigsen De Haindl | |
CN2224628Y (en) * | 1994-10-26 | 1996-04-17 | 周正龙 | Automatic syringe with dual springs |
IL148899A0 (en) | 1999-09-29 | 2002-09-12 | Sterling Medivations Inc | Reusable medication delivery device |
FR2799374B1 (en) | 1999-10-08 | 2001-12-07 | Cross Site Technologies | NEEDLELESS SYRINGE WITH FRICTION TRIGGER |
-
2001
- 2001-11-02 US US09/985,466 patent/US7569035B1/en active Active
-
2002
- 2002-11-04 DK DK02773966T patent/DK1441786T3/en active
- 2002-11-04 MX MXPA04004161A patent/MXPA04004161A/en active IP Right Grant
- 2002-11-04 KR KR1020047006620A patent/KR20050043735A/en not_active Application Discontinuation
- 2002-11-04 WO PCT/US2002/035215 patent/WO2003039633A2/en active IP Right Grant
- 2002-11-04 EP EP02773966A patent/EP1441786B1/en not_active Expired - Lifetime
- 2002-11-04 EP EP05024798A patent/EP1627652A3/en not_active Withdrawn
- 2002-11-04 DE DE60217892T patent/DE60217892T2/en not_active Expired - Lifetime
- 2002-11-04 CA CA2465443A patent/CA2465443C/en not_active Expired - Fee Related
- 2002-11-04 ES ES02773966T patent/ES2281544T3/en not_active Expired - Lifetime
- 2002-11-04 IL IL16168102A patent/IL161681A0/en not_active IP Right Cessation
- 2002-11-04 CN CNB02825130XA patent/CN100406076C/en not_active Expired - Fee Related
- 2002-11-04 EP EP05024799A patent/EP1627653A3/en not_active Withdrawn
- 2002-11-04 AU AU2002336714A patent/AU2002336714B2/en not_active Ceased
- 2002-11-04 AT AT02773966T patent/ATE352335T1/en not_active IP Right Cessation
- 2002-11-04 JP JP2003541922A patent/JP2005508232A/en active Pending
Patent Citations (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US648858A (en) * | 1900-03-14 | 1900-05-01 | Charles B Dolge | Embalming-needle. |
US2590895A (en) * | 1949-11-21 | 1952-04-01 | Louis A Scarpellino | Myelographic needle |
US2711733A (en) * | 1951-08-10 | 1955-06-28 | Jr George W Jacoby | Hypodermic needle |
US2634726A (en) * | 1952-01-30 | 1953-04-14 | Ralph D Hanson | Hypodermic needle |
US2748769A (en) * | 1953-02-24 | 1956-06-05 | Huber Jennie | Hypodermic needle |
US2746454A (en) * | 1953-05-04 | 1956-05-22 | Hans W Sorensen | Intravenous needle |
US2737948A (en) * | 1954-08-23 | 1956-03-13 | Pfizer & Co C | Disposable cartridge for hypodermic syringe |
US2745403A (en) * | 1954-10-14 | 1956-05-15 | Samuel D Goldberg | Disposable cartridge type syringe |
US2936756A (en) * | 1955-07-01 | 1960-05-17 | Gabriel Daniel | Hypodermic needle unit for discharge of medications from pressurized vials |
US3492992A (en) * | 1969-03-26 | 1970-02-03 | Deknatel Inc | Hypodermic needle |
US3788119A (en) * | 1972-08-17 | 1974-01-29 | Baxter Laboratories Inc | Method of forming spinal needle |
US4413993A (en) * | 1973-07-30 | 1983-11-08 | Guttman Yolan R | Infiltration-proof intravenous needle |
US3924617A (en) * | 1973-09-28 | 1975-12-09 | Crinospital Spa | Aspiration and infusion needle |
US4381779A (en) * | 1981-07-16 | 1983-05-03 | Sterling Drug Inc. | Deformable slidable piston to provide self-aspiration in hypodermic cartridge ampoules |
US4394863A (en) * | 1981-10-23 | 1983-07-26 | Survival Technology, Inc. | Automatic injector with cartridge having separate sequentially injectable medicaments |
US4661098A (en) * | 1982-10-27 | 1987-04-28 | Duphar International Research B.V. | Automatic injection device |
US4490139A (en) * | 1983-01-28 | 1984-12-25 | Eli Lilly And Company | Implant needle and method |
US4537593A (en) * | 1983-06-06 | 1985-08-27 | Becton, Dickinson And Co. | Self-venting, non-coring needle assembly |
US4808170A (en) * | 1985-12-16 | 1989-02-28 | Alcon Laboratories, Inc. | Hypotraumatic injection needle useful in ophthalmic surgery |
US4968302A (en) * | 1986-07-01 | 1990-11-06 | Eberhardt Schluter | Automatic injection device, including an ampoule or a cartridge for an injection device |
US4826170A (en) * | 1987-02-23 | 1989-05-02 | Overman Enterprises Inc. | Liar's dice box |
US4889529A (en) * | 1987-07-10 | 1989-12-26 | B. Braun Melsungen Ag | Needle |
US4969877A (en) * | 1988-10-19 | 1990-11-13 | The Pascall Medical Corporation | Syringe |
US5102393A (en) * | 1989-07-17 | 1992-04-07 | Survival Technology, Inc. | Autoinjector converted from intramuscular to subcutaneous mode of injection |
US5391151A (en) * | 1991-01-15 | 1995-02-21 | Survival Technology, Inc. | Subcutaneous injector |
US5709668A (en) * | 1991-01-16 | 1998-01-20 | Senetek Plc | Automatic medicament injector employing non-coring needle |
US5290267A (en) * | 1991-01-17 | 1994-03-01 | Fresenius Ag | Hypodermic needle |
US5354286A (en) * | 1993-12-07 | 1994-10-11 | Survival Technology, Inc. | Injection device having polyparaxylylene coated container |
US5533993A (en) * | 1994-10-05 | 1996-07-09 | International Medication Systems, Limited | Medication injector with protected cannula and Y-site lockout |
US5575780A (en) * | 1995-04-28 | 1996-11-19 | Saito; Yoshikuni | Medical hollow needle and a method of producing thereof |
US5820609A (en) * | 1995-04-28 | 1998-10-13 | Saito; Yoshikuni | Medical hollow needle and a method of producing thereof |
US5968022A (en) * | 1995-04-28 | 1999-10-19 | Saito; Yoshikuni | Medical hollow needle and method of production |
US6213989B1 (en) * | 1995-07-28 | 2001-04-10 | Dsu Medical Corporation | Hypodermic cannula |
US5716348A (en) * | 1995-10-19 | 1998-02-10 | Meridian Medical Technologies, Inc. | Anti-coring needle |
US6004300A (en) * | 1997-08-28 | 1999-12-21 | Butcher; Robert M | Composite hypodermic syringe piston |
US6702791B1 (en) * | 1999-02-04 | 2004-03-09 | Integ, Inc. | Needle for body fluid tester |
US6626887B1 (en) * | 1999-06-08 | 2003-09-30 | Intravantage, Inc. | Hard tissue drug delivery device and method |
US7070583B1 (en) * | 2000-07-03 | 2006-07-04 | Dr. Japan Co., Ltd. | Medical bevel needle |
US20080154217A1 (en) * | 2005-02-03 | 2008-06-26 | Vygon | Puncture Tips And Catheter Tubes |
Cited By (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9056170B2 (en) | 2004-11-22 | 2015-06-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US8920377B2 (en) | 2004-11-22 | 2014-12-30 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US11590286B2 (en) | 2004-11-22 | 2023-02-28 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US8313466B2 (en) | 2004-11-22 | 2012-11-20 | Intelliject, Inc. | Devices, systems and methods for medicament delivery |
US8361029B2 (en) | 2004-11-22 | 2013-01-29 | Intelliject, Llc | Devices, systems and methods for medicament delivery |
US8425462B2 (en) | 2004-11-22 | 2013-04-23 | Intelliject, Inc. | Devices, systems, and methods for medicament delivery |
US10737028B2 (en) | 2004-11-22 | 2020-08-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US10071203B2 (en) | 2004-11-22 | 2018-09-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US10335549B2 (en) | 2004-11-22 | 2019-07-02 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US10314977B2 (en) | 2004-11-22 | 2019-06-11 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9833573B2 (en) | 2004-11-22 | 2017-12-05 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9352091B2 (en) | 2004-11-22 | 2016-05-31 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9737669B2 (en) | 2004-11-22 | 2017-08-22 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US9149579B2 (en) | 2004-11-22 | 2015-10-06 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US10918791B2 (en) | 2005-02-01 | 2021-02-16 | Kaleo, Inc. | Devices, systems and methods for medicament delivery |
US20110172636A1 (en) * | 2007-08-17 | 2011-07-14 | Aasmul Soeren | Injection apparatus and special needle for making an injection at a predetermined depth in the skin |
US9597461B2 (en) | 2007-08-17 | 2017-03-21 | Medtronic Minimed, Inc. | Injection apparatus and special needle for making an injection at a predetermined depth in the skin |
US10124117B2 (en) * | 2008-05-05 | 2018-11-13 | Becton, Dickinson And Company | Drug delivery device having cartridge with enlarged distal end |
US20110092917A1 (en) * | 2008-05-05 | 2011-04-21 | Becton, Dickinson And Company | Drug delivery device having cartridge with enlarged distal end |
US20100185178A1 (en) * | 2009-01-20 | 2010-07-22 | Robert Sharp | Injection device |
US8734402B2 (en) | 2009-01-20 | 2014-05-27 | Future Injection Technologies Limited | Injection device |
USD994110S1 (en) | 2011-01-26 | 2023-08-01 | Kaleo, Inc. | Medicament delivery device cover |
US10238806B2 (en) | 2011-01-26 | 2019-03-26 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US9814838B2 (en) | 2011-01-26 | 2017-11-14 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US10342924B2 (en) | 2011-01-26 | 2019-07-09 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US8939943B2 (en) | 2011-01-26 | 2015-01-27 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US10322239B2 (en) | 2011-01-26 | 2019-06-18 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
USD1011520S1 (en) | 2011-01-26 | 2024-01-16 | Kaleo, Inc. | Medicament delivery device and cover assembly |
US9084849B2 (en) | 2011-01-26 | 2015-07-21 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US11426520B2 (en) | 2011-01-26 | 2022-08-30 | Kaleo, Inc. | Medicament delivery devices for administration of a medicament within a prefilled syringe |
US10143792B2 (en) | 2011-02-28 | 2018-12-04 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9022022B2 (en) | 2011-02-28 | 2015-05-05 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US9474869B2 (en) | 2011-02-28 | 2016-10-25 | Kaleo, Inc. | Medicament delivery device for administration of opioid antagonists including formulations for naloxone |
US12138053B2 (en) | 2012-01-25 | 2024-11-12 | Tasso, Inc. | Methods, systems, and devices relating to open microfluidic channels |
US11395614B2 (en) | 2012-01-25 | 2022-07-26 | Tasso, Inc. | Methods, systems, and devices relating to open microfluidic channels |
US9931472B2 (en) | 2012-04-17 | 2018-04-03 | Universiteit Antwerpen | Intradermal injection device |
US20160051981A1 (en) * | 2012-07-23 | 2016-02-25 | Tasso, Inc. | Methods, Systems, and Devices Relating to Open Microfluidic Channels |
US9987629B2 (en) * | 2012-07-23 | 2018-06-05 | Tasso, Inc. | Methods, systems, and devices relating to open microfluidic channels |
US9545485B2 (en) * | 2013-03-26 | 2017-01-17 | Terumo Kabushiki Kaisha | Elastic cap and syringe assembly therewith |
US20150174337A1 (en) * | 2013-03-26 | 2015-06-25 | Terumo Kabushiki Kaisha | Elastic cap and syringe assembly therewith |
US9808584B2 (en) | 2013-03-26 | 2017-11-07 | Terumo Kabushiki Kaisha | Elastic cap and syringe assembly therewith |
US10220158B2 (en) | 2014-07-18 | 2019-03-05 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
US9517307B2 (en) | 2014-07-18 | 2016-12-13 | Kaleo, Inc. | Devices and methods for delivering opioid antagonists including formulations for naloxone |
US11033212B2 (en) | 2014-08-01 | 2021-06-15 | Tasso, Inc. | Devices, systems and methods for gravity-enhanced microfluidic collection, handling and transferring of fluids |
US12127837B2 (en) | 2014-08-01 | 2024-10-29 | Tasso, Inc. | Devices, systems and methods for gravity-enhanced microfluidic collection, handling and transferring of fluids |
US11998334B2 (en) | 2014-08-01 | 2024-06-04 | Tasso, Inc. | Devices, systems and methods for gravity-enhanced microfluidic collection, handling and transferring of fluids |
US10576206B2 (en) | 2015-06-30 | 2020-03-03 | Kaleo, Inc. | Auto-injectors for administration of a medicament within a prefilled syringe |
US11517674B2 (en) | 2015-06-30 | 2022-12-06 | Kaleo, Inc. | Auto-injectors for administration of a medicament within a prefilled syringe |
CN105169534A (en) * | 2015-08-10 | 2015-12-23 | 苏州灵岩医疗科技股份有限公司 | Needle tip for injection |
US11642057B2 (en) | 2015-12-21 | 2023-05-09 | Tasso, Inc. | Devices, systems and methods for actuation and retraction in fluid collection |
US11413405B2 (en) | 2016-04-01 | 2022-08-16 | Idevax Bv | Injection device |
US11771830B2 (en) | 2016-12-23 | 2023-10-03 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
US10688244B2 (en) | 2016-12-23 | 2020-06-23 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
US10842938B2 (en) | 2016-12-23 | 2020-11-24 | Kaleo, Inc. | Medicament delivery device and methods for delivering drugs to infants and children |
US12048836B2 (en) | 2018-04-19 | 2024-07-30 | Sanofi | Force reduction in injection devices |
US11510659B2 (en) | 2018-09-14 | 2022-11-29 | Tasso, Inc. | Bodily fluid collection devices and related methods |
US12017047B2 (en) | 2019-08-09 | 2024-06-25 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
US11167087B2 (en) | 2019-08-09 | 2021-11-09 | Kaleo, Inc. | Devices and methods for delivery of substances within a prefilled syringe |
Also Published As
Publication number | Publication date |
---|---|
EP1627653A3 (en) | 2007-04-04 |
CA2465443A1 (en) | 2003-05-15 |
EP1627653A2 (en) | 2006-02-22 |
DK1441786T3 (en) | 2007-05-29 |
WO2003039633A3 (en) | 2004-01-15 |
KR20050043735A (en) | 2005-05-11 |
MXPA04004161A (en) | 2005-01-25 |
WO2003039633A2 (en) | 2003-05-15 |
EP1627652A3 (en) | 2007-04-04 |
ATE352335T1 (en) | 2007-02-15 |
DE60217892T2 (en) | 2007-10-31 |
AU2002336714B2 (en) | 2008-02-28 |
EP1627652A2 (en) | 2006-02-22 |
CA2465443C (en) | 2011-05-03 |
ES2281544T3 (en) | 2007-10-01 |
EP1441786A2 (en) | 2004-08-04 |
IL161681A0 (en) | 2004-09-27 |
DE60217892D1 (en) | 2007-03-15 |
US7569035B1 (en) | 2009-08-04 |
EP1441786B1 (en) | 2007-01-24 |
CN100406076C (en) | 2008-07-30 |
JP2005508232A (en) | 2005-03-31 |
CN1604799A (en) | 2005-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7569035B1 (en) | Automatic injector with anti-coring needle | |
AU2002336714A1 (en) | Automatic injector with anti-coring needle | |
US6409701B1 (en) | Hypodermic syringe with selectively retractable needle | |
US7988663B2 (en) | Retractable needle syringe assembly | |
US6432087B1 (en) | Hypodermic syringe with selectively retractable needle | |
CA2514269C (en) | Retracting needle assembly for a syringe | |
EP1549370B1 (en) | Single use syringe and plunger rod locking device therefor | |
CN105561443B (en) | Retractable needle type injector | |
EP1374936A1 (en) | Hypodermic syringe with selectively retractable needle | |
EP3369447A1 (en) | Grip and syringe assembly | |
AU2008200584A1 (en) | Automatic injector with anti-coring needle | |
US3102539A (en) | Disposable cartridge type hypodermic syringe devices | |
CN107427647A (en) | Injection needle assembly and medication injection device | |
US20230390500A1 (en) | Medication administration device | |
CN110167617B (en) | Needle cannula, injection needle assembly and injection device comprising same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MERIDIAN MEDICAL TECHNOLOGIES, INC., MARYLAND Free format text: SECURITY RELEASE;ASSIGNOR:FLEET NATIONAL BANK;REEL/FRAME:014885/0553 Effective date: 20030422 |
|
AS | Assignment |
Owner name: CREDIT SUISSE, AS AGENT,NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:022034/0922 Effective date: 20081229 Owner name: CREDIT SUISSE, AS AGENT, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:022034/0922 Effective date: 20081229 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: CREDIT SUISSE, AS AGENT, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:023456/0990 Effective date: 20091029 |
|
FEPP | Fee payment procedure |
Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: CREDIT SUISSE AG,NEW YORK Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:024369/0032 Effective date: 20100511 Owner name: CREDIT SUISSE AG,NEW YORK Free format text: RELEASE OF SECURITY INTEREST (10/09);ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:024369/0119 Effective date: 20100511 Owner name: CREDIT SUISSE AG, NEW YORK Free format text: RELEASE OF SECURITY INTEREST (10/09);ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:024369/0119 Effective date: 20100511 Owner name: CREDIT SUISSE AG, NEW YORK Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:024369/0032 Effective date: 20100511 |
|
AS | Assignment |
Owner name: CREDIT SUISSE AG,NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:024379/0816 Effective date: 20100511 Owner name: CREDIT SUISSE AG, NEW YORK Free format text: SECURITY AGREEMENT;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:024379/0816 Effective date: 20100511 |
|
CC | Certificate of correction | ||
AS | Assignment |
Owner name: MERIDIAN MEDICAL TECHNOLOGIES, INC., MARYLAND Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:CREDIT SUISSE AG;REEL/FRAME:025741/0482 Effective date: 20110131 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FPAY | Fee payment |
Year of fee payment: 8 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 12 |
|
AS | Assignment |
Owner name: MERIDIAN MEDICAL TECHNOLOGIES, LLC, MARYLAND Free format text: ENTITY CONVERSION;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, INC.;REEL/FRAME:059727/0945 Effective date: 20211231 |
|
AS | Assignment |
Owner name: JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT, ILLINOIS Free format text: SECURITY INTEREST;ASSIGNOR:MERIDIAN MEDICAL TECHNOLOGIES, LLC;REEL/FRAME:062089/0698 Effective date: 20221212 |